View Filing Data

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 28, 2019	Oct. 28, 2019
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-28
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 28, 2019
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		146,740,149

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 29, 2018
Current assets:
Cash and cash equivalents	$ 75,256	$ 56,885
Accounts receivable, net of reserves of $55,116 and $53,121	1,278,939	1,168,776
Inventories, net	1,356,897	1,415,512
Prepaid expenses and other	404,650	451,033
Assets of discontinued operations	0	1,083,014
Total current assets	3,115,742	4,175,220
Property and equipment, net	311,123	314,221
Operating lease right-of-use assets	240,126	0
Goodwill	2,441,175	2,081,029
Other intangibles, net	603,172	376,031
Investments and other	385,744	420,367
Assets of discontinued operations	0	1,133,659
Total assets	7,097,082	8,500,527
Current liabilities:
Accounts payable	854,658	785,756
Bank credit lines	107,841	951,458
Current maturities of long-term debt	109,188	8,280
Operating lease liabilities	67,374	0
Liabilities of discontinued operations	0	577,607
Accrued expenses:
Payroll and related	230,239	242,876
Taxes	111,051	154,613
Other	428,341	498,237
Total current liabilities	1,908,692	3,218,827
Long-term debt	872,229	980,344
Deferred income taxes	68,643	27,218
Operating lease liabilities	182,505	0
Other liabilities	322,378	357,741
Liabilities of discontinued operations	0	62,453
Total liabilities	3,354,447	4,646,583
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Redeemable noncontrolling interests	283,325	219,724
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $.01 par value, 480,000,000 shares authorized, 146,254,864 outstanding on September 28, 2019 and 151,401,668 outstanding on December 29, 2018	1,463	1,514
Additional paid-in capital	65,641	0
Retained earnings	2,957,850	3,208,589
Accumulated other comprehensive income (loss)	(195,426)	(248,771)
Total Henry Schein, Inc. stockholders' equity	2,829,528	2,961,332
Noncontrolling interests	629,782	580,456
Total stockholders' equity	3,459,310	3,541,788
Total liabilities, redeemable noncontrolling interests and stockholders' equity	7,097,082	8,500,527
Henry Schein Animal Health Business [Member]
Current assets:
Assets of discontinued operations		1,083,014
Operating lease right-of-use assets		0
Investments and other		118,003
Assets of discontinued operations		1,133,659
Current liabilities:
Current maturities of long-term debt		675
Operating lease liabilities		0
Liabilities of discontinued operations		577,607
Accrued expenses:
Long-term debt		23,529
Operating lease liabilities		0
Liabilities of discontinued operations		62,453
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Redeemable noncontrolling interests	$ 0	$ 92,432

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 29, 2018
Current assets:
Accounts receivable, reserves (in dollars)	$ 55,116	$ 53,121
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	146,254,864	151,401,668

CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
CONSOLIDATED STATEMENTS OF INCOME
Net sales	$ 2,508,767	$ 2,355,565	$ 7,316,862	$ 6,945,047
Cost of sales	1,747,600	1,633,206	5,036,574	4,785,231
Gross profit	761,167	722,359	2,280,288	2,159,816
Operating expenses:
Selling, general and administrative	574,771	552,051	1,742,597	1,658,988
Litigation settlements	0	38,488	0	38,488
Restructuring costs (credits)	(802)	8,551	15,764	19,723
Operating income	187,198	123,269	521,927	442,617
Other income (expense):
Interest income	3,943	3,928	12,368	11,105
Interest expense	(12,373)	(20,430)	(41,459)	(54,569)
Other, net	(177)	(586)	(2,012)	(1,773)
Income from continuing operations before taxes and equity in earnings of affiliates and noncontrolling interest	178,591	106,181	490,824	397,380
Income taxes	(41,964)	(16,633)	(117,326)	(86,654)
Equity in earnings of affiliates	6,585	6,699	14,771	14,829
Income from continuing operations	143,212	96,247	388,269	325,555
Income (loss) from discontinued operations	5,641	30,729	(5,576)	97,561
Net income	148,853	126,976	382,693	423,116
Less: Net income attributable to noncontrolling interests	(8,296)	(5,477)	(18,187)	(12,615)
Less: Net (income) loss attributable to noncontrolling interests from discontinued operations	0	(21)	366	(7,593)
Net income attributable to Henry Schein, Inc.	140,557	121,478	364,872	402,908
Continuing operations	134,916	90,770	370,082	312,940
Discontinued operations	5,641	30,708	(5,210)	89,968
Net income attributable to Henry Schein, Inc.	$ 140,557	$ 121,478	$ 364,872	$ 402,908
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 0.92	$ 0.60	$ 2.49	$ 2.05
Diluted (in dollars per share)	0.91	0.59	2.47	2.03
Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	0.04	0.20	(0.04)	0.59
Diluted (in dollars per share)	0.04	0.20	(0.04)	0.58
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	0.96	0.80	2.46	2.63
Diluted (in dollars per share)	$ 0.95	$ 0.79	$ 2.43	$ 2.62
Weighted-average common shares outstanding:
Basic (in shares)	147,136	152,533	148,603	152,970
Diluted (in shares)	148,575	153,614	149,920	153,982

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 148,853	$ 126,976	$ 382,693	$ 423,116
Other comprehensive income (loss), net of tax:
Foreign currency translation loss	(60,635)	(10,582)	(43,926)	(106,154)
Unrealized gain (loss) from foreign currency hedging activities	(1,263)	(379)	(1,586)	674
Unrealized investment gain (loss)	2	(1)	8	(2)
Pension adjustment gain	400	116	832	1,056
Other Comprehensive Income, net of tax	(61,496)	(10,846)	(44,672)	(104,426)
Comprehensive income	87,357	116,130	338,021	318,690
Comprehensive income attributable to noncontrolling interests:
Net income	(8,296)	(5,498)	(17,821)	(20,208)
Foreign currency translation loss	6,014	2,589	4,609	14,844
Comprehensive income attributable to noncontrolling interests	(2,282)	(2,909)	(13,212)	(5,364)
Comprehensive income attributable to Henry Schein, Inc.	$ 85,075	$ 113,221	$ 324,809	$ 313,326

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Cumulative impact of adopting new accounting standards	$ 2,594	$ 0	$ 0	$ 2,594	$ 0	$ 0
Beginning Balance at Dec. 30, 2017	2,824,410	$ 1,537	0	2,940,029	(130,067)	12,911
Beginning Balance, shares (in shares) at Dec. 30, 2017		153,690,146
Net income (excluding attributable to Redeemable noncontrolling interests from continuing and discontinued operations)	406,097	$ 0	0	402,908	0	3,189
Foreign currency translation loss (excluding loss attributable to Redeemable noncontrolling interests and discontinued operations)	(92,402)	0	0	0	(91,310)	(1,092)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	674	0	0	0	674	0
Unrealized investment gain (loss), net of tax impact	(2)	0	0	0	(2)	0
Pension adjustment gain (loss), net of tax impact	1,056	0	0	0	1,056	0
Dividends paid	(396)	0	0	0	0	(396)
Other adjustments	701	0	(11)	0	0	712
Purchase of noncontrolling interests	(207)	0	0	0	0	(207)
Change in fair value of redeemable securities	(119,695)	0	(119,695)	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	428,464	0	0	0	0	428,464
Repurchase and retirement of common stock - Value	(114,106)	$ (15)	(20,865)	(93,226)	0	0
Repurchase and retirement of common stock - Shares		(1,521,208)
Stock issued upon exercise of stock options	3,076	$ 1	3,075	0	0	0
Stock issued upon exercise of stock options, shares		153,516
Stock-based compensation expense - Value	(34,235)	$ (4)	(34,231)	0	0	0
Stock-based compensation expense - Shares		379,428
Shares withheld for payroll taxes - Value	(18,110)	$ (3)	(18,107)	0	0	0
Shares withheld for payroll taxes - Shares		(267,573)
Settlement of stock-based compensation awards	(642)	$ 0	(642)	0	0	0
Settlement of stock-based compensation awards, shares		3,371
Deferred tax benefit arising from acquisition of noncontrolling interest in partnership	60,969	$ 0	60,969	0	0	0
Transfer of charges in excess of capital	0	0	61,045	(61,045)	0	0
Ending Balance at Sep. 29, 2018	3,416,716	$ 1,524	0	3,191,260	(219,649)	443,581
Ending Balance, shares (in shares) at Sep. 29, 2018		152,437,680
Beginning Balance at Jun. 30, 2018	2,922,909	$ 1,532	0	3,123,398	(211,392)	9,371
Beginning Balance, shares (in shares) at Jun. 30, 2018		153,231,669
Net income (excluding attributable to Redeemable noncontrolling interests from continuing and discontinued operations)	124,328	$ 0	0	121,478	0	2,850
Foreign currency translation loss (excluding loss attributable to Redeemable noncontrolling interests and discontinued operations)	(8,365)	0	0	0	(7,993)	(372)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(379)	0	0	0	(379)	0
Unrealized investment gain (loss), net of tax impact	(1)	0	0	0	(1)	0
Pension adjustment gain (loss), net of tax impact	116	0	0	0	116	0
Dividends paid	(72)	0	0	0	0	(72)
Other adjustments	(16)	0	12	0	0	(28)
Purchase of noncontrolling interests	8	0	0	0	0	8
Change in fair value of redeemable securities	(2,988)	0	(2,988)	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	431,824	0	0	0	0	431,824
Repurchase and retirement of common stock - Value	(60,751)	$ (7)	(10,625)	(50,119)	0	0
Repurchase and retirement of common stock - Shares		(751,928)
Stock issued upon exercise of stock options	54	$ 1	55	0	0	0
Stock issued upon exercise of stock options, shares		2,000
Stock-based compensation expense - Value	(10,890)	$ 0	(10,890)	0	0	0
Stock-based compensation expense - Shares		(40,017)
Shares withheld for payroll taxes - Value	(421)	$ 0	(421)	0	0	0
Shares withheld for payroll taxes - Shares		(4,044)
Settlement of stock-based compensation awards	(420)	$ 0	(420)	0	0	0
Settlement of stock-based compensation awards, shares		0
Transfer of charges in excess of capital	0	$ 0	3,497	(3,497)	0	0
Ending Balance at Sep. 29, 2018	3,416,716	$ 1,524	0	3,191,260	(219,649)	443,581
Ending Balance, shares (in shares) at Sep. 29, 2018		152,437,680
Cumulative impact of adopting new accounting standards	(274)	$ 0	0	(274)	0	0
Beginning Balance at Dec. 29, 2018	$ 3,541,788	$ 1,514	0	3,208,589	(248,771)	580,456
Beginning Balance, shares (in shares) at Dec. 29, 2018	151,401,668	151,401,668
Net income (excluding attributable to Redeemable noncontrolling interests from continuing and discontinued operations)	$ 372,441	$ 0	0	364,872	0	7,569
Foreign currency translation loss (excluding loss attributable to Redeemable noncontrolling interests and discontinued operations)	(39,606)	0	0	0	(39,317)	(289)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(1,586)	0	0	0	(1,586)	0
Unrealized investment gain (loss), net of tax impact	8	0	0	0	8	0
Pension adjustment gain (loss), net of tax impact	832	0	0	0	832	0
Dividends paid	(299)	0	0	0	0	(299)
Other adjustments	(3)	0	(3)	0	0	0
Change in fair value of redeemable securities	5,867	0	5,867	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	42,345	0	0	0	0	42,345
Repurchase and retirement of common stock - Value	(325,000)	$ (52)	(51,312)	(273,636)	0	0
Repurchase and retirement of common stock - Shares		(5,277,256)
Adjustment for Animal Health Spin-off, Value	1	$ 1	0	0	0	0
Adjustment for Animal Health Spin-off, Shares		87,629
Stock issued upon exercise of stock options	34	$ 0	34	0	0	0
Stock issued upon exercise of stock options, shares		2,526
Stock-based compensation expense - Value	(33,435)	$ (2)	(33,433)	0	0	0
Stock-based compensation expense - Shares		218,563
Shares withheld for payroll taxes - Value	(10,767)	$ (2)	(10,765)	0	0	0
Shares withheld for payroll taxes - Shares		(178,266)
Settlement of stock-based compensation awards	303	$ 0	303	0	0	0
Settlement of stock-based compensation awards, shares		0
Share Sale related to Animal Health business	361,090	$ 0	361,090	0	0	0
Separation of Animal Health business	(521,299)	0	(71,549)	(543,158)	93,408	0
Transfer of charges in excess of capital	0	0	(201,457)	201,457	0	0
Ending Balance at Sep. 28, 2019	$ 3,459,310	$ 1,463	65,641	2,957,850	(195,426)	629,782
Ending Balance, shares (in shares) at Sep. 28, 2019	146,254,864	146,254,864
Beginning Balance at Jun. 29, 2019	$ 3,446,214	$ 1,478	65,356	2,900,387	(139,944)	618,937
Beginning Balance, shares (in shares) at Jun. 29, 2019		147,823,846
Net income (excluding attributable to Redeemable noncontrolling interests from continuing and discontinued operations)	144,748	$ 0	0	140,557	0	4,191
Foreign currency translation loss (excluding loss attributable to Redeemable noncontrolling interests and discontinued operations)	(54,887)	0	0	0	(54,621)	(266)
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	(1,263)	0	0	0	(1,263)	0
Unrealized investment gain (loss), net of tax impact	2	0	0	0	2	0
Pension adjustment gain (loss), net of tax impact	400	0	0	0	400	0
Dividends paid	(84)	0	0	0	0	(84)
Other adjustments	1	0	1	0	0	0
Change in fair value of redeemable securities	1,667	0	1,667	0	0	0
Initial noncontrolling interests and adjustments related to business acquisitions	7,004	0	0	0	0	7,004
Repurchase and retirement of common stock - Value	(98,218)	$ (15)	(15,109)	(83,094)	0	0
Repurchase and retirement of common stock - Shares		(1,571,909)
Stock-based compensation expense - Value	(13,338)	$ 0	(13,338)	0	0	0
Stock-based compensation expense - Shares		6,028
Shares withheld for payroll taxes - Value	(199)	$ 0	(199)	0	0	0
Shares withheld for payroll taxes - Shares		(3,101)
Settlement of stock-based compensation awards	(85)	$ 0	(85)	0	0	0
Separation of Animal Health business	672	0	672	0	0	0
Ending Balance at Sep. 28, 2019	$ 3,459,310	$ 1,463	$ 65,641	$ 2,957,850	$ (195,426)	$ 629,782
Ending Balance, shares (in shares) at Sep. 28, 2019	146,254,864	146,254,864

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 28, 2019	Sep. 28, 2019
Statement of Stockholders' Equity [Abstract]
Unrealized loss from foreign currency hedging activities, tax benefit	$ 422	$ 451
Unrealized investment gain, (tax benefit) tax	1	2
Pension adjustment gain, tax benefit (tax)	185	314
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to Redeemable noncontrolling interests		10,618
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests	(5,748)	(4,912)
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to Redeemable noncontrolling interests	$ 4,105	10,618
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests		(4,912)
Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to Redeemable noncontrolling interests		366
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests		$ 592

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018
Cash flows from operating activities:
Net income	$ 382,693	$ 423,116
Income (loss) from discontinued operations	(5,576)	97,561
Income from continuing operations	388,269	325,555
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	136,210	106,930
Stock-based compensation expense	33,110	30,570
Provision for losses on trade and other accounts receivable	7,576	7,400
Provision for deferred income taxes	(3,468)	(3,768)
Equity in earnings of affiliates	(14,771)	(14,829)
Distributions from equity affiliates	67,913	14,585
Changes in unrecognized tax benefits	3,535	2,853
Other	(2,122)	503
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(115,384)	(141,017)
Inventories	75,093	(59,794)
Other current assets	(70,348)	(58,856)
Accounts payable and accrued expenses	19,567	59,263
Net cash provided by operating activities from continuing operations	525,180	269,395
Net cash provided by operating activities from continuing operations	525,180	269,395
Net cash provided by (used in) operating activities from discontinued operations	(163,653)	121,359
Net cash provided by operating activities	361,527	390,754
Cash flows from investing activities:
Purchases of fixed assets	(48,956)	(49,319)
Payments for equity investments and business acquisitions, net of cash acquired	(657,093)	(38,996)
Proceeds from sale of equity investment	10,500	0
Proceeds/(payments) for loan to affiliate	16,448	(24,200)
Other	(12,248)	(11,557)
Net cash used in investing activities from continuing operations	(691,349)	(124,072)
Net cash used in investing activities from continuing operations	(691,349)	(124,072)
Net cash used in investing activities from discontinued operations	(2,064)	(22,285)
Net cash used in investing activities	(693,413)	(146,357)
Cash flows from financing activities:
Proceeds from (repayments of) bank borrowings	(843,846)	404,098
Proceeds from issuance of debt	741	115,000
Principal payments for long-term debt	(10,252)	(24,483)
Debt issuance costs	(391)	(395)
Proceeds from issuance of stock upon exercise of stock options	34	3,076
Payments for repurchases of common stock	(325,000)	(114,106)
Payments for taxes related to shares withheld for employee taxes	(10,751)	(17,903)
Distribution received related to Animal Health Spin-off	1,120,000	0
Proceeds related to Animal Health Share Sale	361,090	0
Proceeds from (distributions to) noncontrolling stockholders	53,429	(6,142)
Acquisitions of noncontrolling interests in subsidiaries	(2,358)	(286,233)
Payments to Henry Schein Animal Health Business	(166,557)	(292,806)
Net cash provided by financing activities from continuing operations	176,139	(219,894)
Net cash provided by (used in) financing activities from continuing operations	176,139	(219,894)
Net cash provided by (used in) financing activities from discontinued operations	144,633	(98,622)
Net cash provided by (used in) financing activities	320,772	(318,516)
Effect of exchange rate changes on cash and cash equivalents-continuing operations	8,401	14,505
Effect of exchange rate changes on cash and cash equivalents-discontinued operations	(2,240)	4,696
Net change in cash and cash equivalents from continuing operations	18,371	(60,066)
Net change in cash and cash equivalents from discontinued operations	(23,324)	5,148
Net change in cash and cash equivalents	(4,953)	(54,918)
Cash and cash equivalents, beginning of period	56,885	158,002
Cash and cash equivalents, end of period	$ 75,256	$ 97,936

Basis of Presentation

9 Months Ended

Sep. 28, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Note 1 – Basis of Presentation

Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation.

Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.

We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements.

For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At September 28, 2019 and December 29, 2018, trade accounts receivable that can only be used to settle obligations of this VIE were $419 million and $422 million, respectively, and the liabilities of the VIE where the creditors have recourse to us were $350 million and $350 million, respectively.

The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 29, 2018.

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”) (the “Merger”). All financial information within this Form 10-Q presents the Henry Schein Animal Health Business as a discontinued operation.

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the nine months ended September 28, 2019 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2019.

Discontinued Operations

9 Months Ended

Sep. 28, 2019

Discontinued Operations

Discontinued Operations

Note 2 – Discontinued Operations

Animal Health Spin-off

On the Distribution Date, we completed the Separation and subsequent Merger of the Henry Schein Animal Health Business with Vets First Choice. This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63% of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37% of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market.

In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services.

As a result of the Separation, the financial position and results of operations of the Henry Schein Animal Health Business are presented as discontinued operations and have been excluded from continuing operations and segment results for all periods presented. The accompanying Notes to the Consolidated Financial Statements have been revised to reflect the effect of the Separation and all prior year balances have been revised accordingly to reflect continuing operations only. The historical statements of Comprehensive Income (Loss) and Shareholders' Equity have not been revised to reflect the Separation and instead reflect the Separation as an adjustment to the balances at September 28, 2019.

Summarized financial information for our discontinued operations is as follows:

	Three Months Ended				Nine Months Ended
	September 28,		September 29,		September 28,		September 29,
	2019		2018		2019		2018

Net sales	$	-	$	924,114	$	319,522	$	2,881,747
Gross profit		-		166,201		59,425		525,408
Operating income (loss)		(1,063)		42,657		(8,588)		130,800
Income tax expense (benefit)		(6,704)		12,767		(2,023)		37,430
Income (loss) from discontinued operations		5,641		30,729		(5,576)		97,561
Net (income) loss attributable to noncontrolling interests		-		(21)		366		(7,593)
Net income (loss) from discontinued operations
attributable to Henry Schein, Inc.		5,641		30,708		(5,210)		89,968

The financial information above represents activity of the discontinued operations during the quarter through the Distribution Date.

The operating income (loss) from discontinued operations for the three and nine months ended September 28, 2019 was primarily attributable to the inclusion of approximately $0.3 million and $23.4 million, respectively, of transaction costs directly related to the Animal Health Spin-off.

The income from discontinued operations for the three months ended September 28, 2019 was primarily attributable a change in estimate of the tax deductibility of transaction costs incurred that were directly related to the Animal Health Spin-off. The loss from discontinued operations for the nine months ended September 28, 2019 was primarily attributable to the inclusion of the transaction costs directly related to the Animal Health Spin-off.

The following are the amounts of assets and liabilities that were transferred to Covetrus as of February 7, 2019 and December 29, 2018.

			February 7,		December 29,
			2019		2018
			(unaudited)		(unaudited)

Cash and cash equivalents			$	6,815	$	23,324
Accounts receivable, net				432,812		434,935
Inventories, net				536,637		555,230
Prepaid expenses and other				120,546		69,525
		Total current assets of discontinued operations		1,096,810		1,083,014
Property and equipment, net				69,790		68,177
Operating lease right-of-use asset, net				57,012		-
Goodwill				742,931		739,266
Other intangibles, net				205,793		208,213
Investments and other				120,518		118,003
		Total long-term assets of discontinued operations		1,196,044		1,133,659
Total assets of discontinued operations			$	2,292,854	$	2,216,673

Accounts payable			$	316,162	$	441,453
Current maturities of long-term debt				657		675
Operating lease liabilities				18,951		-
Accrued expenses:
	Payroll and related			36,847		36,888
	Taxes			24,060		17,552
	Other			80,400		81,039
		Total current liabilities of discontinued operations		477,077		577,607
Long-term debt				1,176,105		23,529
Deferred income taxes				17,019		4,352
Operating lease liabilities				38,668		-
Other liabilities				29,209		34,572
		Total long-term liabilities of discontinued operations		1,261,001		62,453
Total liabilities of discontinued operations			$	1,738,078	$	640,060
Redeemable noncontrolling interests			$	28,270	$	92,432

Critical Accounting Policies and Estimates and Accounting Pronouncements Adopted

9 Months Ended

Sep. 28, 2019

Critical Accounting Policies and Estimates and Accounting Pronouncements Adopted

Critical Accounting Policies and Estimates and Accounting Pronouncements Adopted

Note 3 – Critical Accounting Policies and Accounting Pronouncements Adopted

Critical Accounting Policies

Except for the accounting policy for leases appearing below, implemented as a result of adopting Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), there have been no material changes in our critical accounting policies during the nine months ended September 28, 2019, as compared to the critical accounting policies described in Item 7 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 29, 2018.

Leases

We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in Property and equipment, Current maturities of long-term debt, and Long-term debt in our consolidated balance sheet.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Leases with a lease term of 12 months or less are not capitalized.

We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.

Accounting Pronouncements Adopted

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02 “Leases (Topic 842)” related to leases requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most significant among the changes in the standard is the recognition of ROU assets and lease liabilities by lessors for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.

We adopted the standard on December 30, 2018 using a modified retrospective approach utilizing a transition relief expedient method whereby we continue to apply existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative-effect adjustment in the period of adoption, rather than in the earliest period presented without adjusting historical financial statements. We elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Information related to leases as of September 28, 2019 is presented under Topic 842, while prior period amounts are not adjusted and continue to be reported under legacy guidance in Topic 840.

The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while our accounting for finance leases remained substantially unchanged.

Adoption of the new standard resulted in the recording of additional net operating lease assets of $259.9 million and operating lease liabilities of $267.3 million, and a decrease of $1.1 million and $8.5 million in prepaid rent and deferred rent liabilities, respectively. The standard did not materially impact our consolidated net income and had no impact on cash flows.

In February 2018, the FASB issued ASU No. 2018-02, "Treatment of Stranded Tax Effects in Accumulated Other Comprehensive Income Resulting From the Tax Cuts and Jobs Act of 2017," which allows the reclassification from accumulated comprehensive income to retained earnings the income tax effects resulting from the Tax Cuts and Jobs Act of 2017 (the “Tax Act”). This ASU is effective for interim and annual reporting periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging” (Topic 815), which simplified the requirements for hedge accounting, more closely aligns hedge accounting risk with risk management activities and increases transparency of the scope and results of hedging activities. This ASU amends the presentation and disclosure requirements and changes how we can assess the effectiveness of our hedging relationships. This ASU will make more financial and nonfinancial hedging strategies eligible for hedge accounting. This ASU is effective for interim and annual reporting periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements.

Revenue from Contracts with Customers

9 Months Ended

Sep. 28, 2019

Revenue from Contracts with Customers

Revenue from Contracts with Customers

Note 4 – Revenue from Contracts with Customers

Revenue is recognized in accordance with policies disclosed in Item 7 of our Annual Report on form 10-K for the year ended December 29, 2018.

Disaggregation of Revenue

The following table disaggregates our revenue by segment and geography:

			Three Months Ended						Nine Months Ended
			September 28, 2019						September 28, 2019
			North America		International		Global		North America		International		Global
Revenues:
	Health care distribution
		Dental	$	951,796	$	594,188	$	1,545,984	$	2,850,762	$	1,843,041	$	4,693,803
		Medical		784,349		19,360		803,709		2,125,002		59,925		2,184,927
		Total health care distribution		1,736,145		613,548		2,349,693		4,975,764		1,902,966		6,878,730
	Technology and value-added services			120,197		17,134		137,331		327,618		50,273		377,891
	Total excluding Corporate TSA revenues ⁽¹⁾			1,856,342		630,682		2,487,024		5,303,382		1,953,239		7,256,621
	Corporate TSA revenues ⁽¹⁾			1,077		20,666		21,743		4,098		56,143		60,241
		Total revenues	$	1,857,419	$	651,348	$	2,508,767	$	5,307,480	$	2,009,382	$	7,316,862

			Three Months Ended						Nine Months Ended
			September 29, 2018						September 29, 2018
			North America		International		Global		North America		International		Global
Revenues:
	Health care distribution
		Dental	$	951,199	$	563,126	$	1,514,325	$	2,830,384	$	1,844,150	$	4,674,534
		Medical		702,758		19,184		721,942		1,915,944		60,423		1,976,367
		Total health care distribution		1,653,957		582,310		2,236,267		4,746,328		1,904,573		6,650,901
	Technology and value-added services			103,955		15,343		119,298		245,761		48,385		294,146
	Total excluding Corporate TSA revenues ⁽¹⁾			1,757,912		597,653		2,355,565		4,992,089		1,952,958		6,945,047
	Corporate TSA revenues ⁽¹⁾			-		-		-		-		-		-
		Total revenues	$	1,757,912	$	597,653	$	2,355,565	$	4,992,089	$	1,952,958	$	6,945,047


(1)	Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

At December 29, 2018, the current portion of contract liabilities of $65.3 million was reported in Accrued expenses: Other, and $5.0 million related to non-current contract liabilities was reported in Other liabilities. During the nine months ended September 28, 2019, we recognized in revenue $55.0 million of the amounts previously deferred at December 29, 2018. At September 28, 2019, the current and non-current portion of contract liabilities were $58.2 million and $4.9 million, respectively.

Segment Data

9 Months Ended

Sep. 28, 2019

Segment Data

Segment Data

Note 5 – Segment Data

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base.

The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 32 countries worldwide.

Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners.

The following tables present information about our reportable and operating segments:

			Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,
			2019		2018		2019		2018
Net Sales:
	Health care distribution ^(1):
		Dental	$	1,545,984	$	1,514,325	$	4,693,803	$	4,674,534
		Medical		803,709		721,942		2,184,927		1,976,367
		Total health care distribution		2,349,693		2,236,267		6,878,730		6,650,901
	Technology and value-added services ⁽²⁾			137,331		119,298		377,891		294,146
		Total excluding Corporate TSA revenue		2,487,024		2,355,565		7,256,621		6,945,047
	Corporate TSA revenues ⁽³⁾			21,743		-		60,241		-
		Total	$	2,508,767	$	2,355,565	$	7,316,862	$	6,945,047


(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.
(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

			Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,
			2019		2018		2019		2018
Operating Income:
	Health care distribution		$	149,497	$	91,306	$	429,026	$	358,978
	Technology and value-added services			37,701		31,963		92,901		83,639
		Total	$	187,198	$	123,269	$	521,927	$	442,617

Debt

9 Months Ended

Sep. 28, 2019

Debt

Debt

Note 6 – Debt

Bank Credit Lines

Bank credit lines consisted of the following:

	September 28,		December 29,
	2019		2018
Revolving credit agreement	$	75,000	$	175,000
Other short-term bank credit lines		32,841		376,458
Committed loan associated with Animal Health Spin-off		-		400,000
Total	$	107,841	$	951,458

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”). This facility, which matures in April 2022, replaced our $500 million revolving credit facility, which was scheduled to mature in September 2019. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect that the LIBOR rate will be discontinued at some point during 2021. We expect to work with our lenders to identify a suitable replacement rate and amend our debt agreements to reflect this new reference rate accordingly. We do not believe that the discontinuation of LIBOR as a reference rate in our debt agreements will have a material adverse effect on our financial position or materially affect our interest expense. Additionally, the Credit Agreement provides, among other things, that we are required to maintain maximum leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September 28, 2019 and December 29, 2018, the borrowings on this revolving credit facility were $75.0 million and $175.0 million, respectively. As of September 28, 2019 and December 29, 2018, there were $9.6 million and $11.2 million of letters of credit, respectively, provided to third parties under the credit facility.

Other Short-Term Credit Lines

As of September 28, 2019 and December 29, 2018, we had various other short-term bank credit lines available, of which $32.8 million and $376.5 million, respectively, were outstanding. At September 28, 2019 and December 29, 2018, borrowings under all of our credit lines had a weighted average interest rate of 2.94% and 3.30%, respectively.

Committed Loan Associated with Animal Health Spin-off

On May 21, 2018, we obtained a $400 million committed loan which matured on the earlier of (i) March 31, 2019 and (ii) the consummation of the Animal Health Spin-off. The proceeds of this loan were used, among other things, to fund our purchase of all of the equity interests in Butler Animal Health Holding Company, LLC (“BAHHC”) directly or indirectly owned by Darby Group Companies, Inc. (“Darby”) and certain other sellers pursuant to the terms of that certain Amendment to Put Rights Agreements, dated as of April 20, 2018, by and among us, Darby, BAHHC and the individual sellers party thereto for an aggregate purchase price of $365 million. As of December 29, 2018, the balance outstanding on this loan was $400 million and is included within the “Bank credit lines” caption within our consolidated balance sheet. At December 29, 2018, the interest rate on this loan was 3.38%. Concurrent with the completion of the Animal Health Spin-off on February 7, 2019, we re-paid the balance of this loan.

Long-term debt

Long-term debt consisted of the following:

		September 28,		December 29,
		2019		2018
Private placement facilities		$	621,217	$	628,189
U.S. trade accounts receivable securitization			350,000		350,000
Various collateralized and uncollateralized loans payable with interest
	in varying installments through 2024 at interest rates
	ranging from 2.56% to 10.5% at September 28,2019 and
	ranging from 2.61% to 4.17% at December 29, 2018		5,995		6,491
Finance lease obligations payable through 2029 with interest rates
	ranging from 1.64% to 19.13% at September 28,2019 and
	ranging from 1.45% to 6.00% at December 29, 2018		4,205		3,944
Total			981,417		988,624
Less current maturities			(109,188)		(8,280)
	Total long-term debt	$	872,229	$	980,344

Private Placement Facilities

On September 15, 2017, we increased our available private placement facilities with three insurance companies to a total facility amount of $1 billion, and extended the expiration date to September 15, 2020. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through September 15, 2020. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

The components of our private placement facility borrowings as of September 28, 2019 are presented in the following table (in thousands):

	Amount of
	Borrowing		Borrowing
Date of Borrowing	Outstanding		Rate		Due Date
September 2, 2010	$	100,000	3.79	%	September 2, 2020
January 20, 2012		50,000	3.45		January 20, 2024
January 20, 2012		21,429	3.09		January 20, 2022
December 24, 2012		50,000	3.00		December 24, 2024
June 2, 2014		100,000	3.19		June 2, 2021
June 16, 2017		100,000	3.42		June 16, 2027
September 15, 2017		100,000	3.52		September 15, 2029
January 2, 2018		100,000	3.32		January 2, 2028
Less: Deferred debt issuance costs		(212)
	$	621,217


(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $350 million, and was previously scheduled to expire on April 29, 2020, has been extended to April 29, 2022. The borrowings outstanding under this securitization facility were $350 million as of both September 28, 2019 and December 29, 2018, respectively. At September 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of2.21 % plus 0.75%, for a combined rate of 2.96%. At December 29, 2018, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 2.66% plus 0.75%, for a combined rate of 3.41%.

We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit.

Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance sheet.

Leases

9 Months Ended

Sep. 28, 2019

Leases

Leases

Note 7 – Leases

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment. Our leases have remaining terms of less than one year to 16 years, some of which may include options to extend the leases for up to 10 years. The components of lease expense were as follows (in thousands):

		Three Months Ended		Nine Months Ended
		September 28,		September 28,
		2019		2019
Operating lease cost:⁽¹⁾		$	21,840	$	68,273
Finance lease cost:
	Amortization of right-of-use assets		290		798
	Interest on lease liabilities		31		88
Total finance lease cost		$	321	$	886


(1)	Includes variable lease expenses.

Supplemental balance sheet information related to leases is as follows:
		September 28,
		2019
Operating Leases:
Operating lease right-of-use assets		$	240,126

Current operating lease liabilities			67,374
Non-current operating lease liabilities			182,505
	Total operating lease liabilities	$	249,879

Finance Leases:
Property and equipment, at cost		$	10,826
Accumulated depreciation			(6,115)
Property and equipment, net of accumulated depreciation		$	4,711

Current maturities of long-term debt		$	1,092
Long-term debt			3,113
	Total finance lease liabilities	$	4,205

Weighted Average Remaining Lease Term in Years:
	Operating leases		5.5
	Finance leases		6.1

Weighted Average Discount Rate:
	Operating leases		3.4	%
	Finance leases		2.2	%

Supplemental cash flow information related to leases is as follows:
		September 28,
		2019
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for operating leases	$	60,275
	Operating cash flows for finance leases		67
	Financing cash flows for finance leases		862
Right-of-use assets obtained in exchange for lease obligations:
	Operating leases ⁽¹⁾	$	281,373
	Finance leases		1,149


(1)	Includes leases that commenced during the nine months ended September 28, 2019, as well as balances related to leases in existence as of the date of the adoption of Topic 842.

Maturities of lease liabilities are as follows:
		September 28,
		2019
		Operating		Finance
		Leases		Leases
2019 (excluding the nine months ended September 28, 2019)	$	21,149	$	453
2020		69,052		1,135
2021		54,082		846
2022		37,886		434
2023		26,051		295
Thereafter		67,075		1,372
Total future lease payments		275,295		4,535
Less imputed interest		(25,416)		(330)
Total	$	249,879	$	4,205

As of September 28, 2019 we have additional operating leases with total lease payments of $6.8 million for buildings and vehicles that have not yet commenced. These operating leases will commence during 2019 with lease terms of two to 10 years.

As previously disclosed in our December 29, 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments under non-cancelable operating leases and capital leases as of December 29, 2018 were as follows (in thousands):

		Operating		Finance
		Leases		Leases
2019	$	62,535	$	976
2020		47,686		801
2021		34,633		501
2022		25,626		305
2023		19,560		283
Thereafter		62,918		1,430
Total minimum lease payments	$	252,958		4,296
Less imputed interest (Capital leases only)				(352)
Total present value of minimum lease payments			$	3,944

Redeemable Noncontrolling Interests

9 Months Ended

Sep. 28, 2019

Redeemable Noncontrolling Interests

Redeemable Noncontrolling Interests

Note 8 – Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ASC Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the nine months ended September 28, 2019 and the year ended December 29, 2018 are presented in the following table:

		September 28,		December 29,
		2019		2018
Balance, beginning of period		$	219,724	$	465,585
Decrease in redeemable noncontrolling interests due to
	redemptions		(2,270)		(287,767)
Increase in redeemable noncontrolling interests due to business
	acquisitions		73,975		4,655
Net income attributable to redeemable noncontrolling interests			10,618		15,327
Dividends declared			(7,943)		(8,206)
Effect of foreign currency translation loss attributable to
	redeemable noncontrolling interests		(4,912)		(11,330)
Change in fair value of redeemable securities			(5,867)		41,460
Balance, end of period		$	283,325	$	219,724

Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a floor amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Comprehensive Income

9 Months Ended

Sep. 28, 2019

Comprehensive Income

Comprehensive Income

Note 9 – Comprehensive Income

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity.

The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:

			September 28,		December 29,
			2019		2018
Attributable to Redeemable noncontrolling interests:
		Foreign currency translation adjustment	$	(22,915)	$	(18,595)

Attributable to noncontrolling interests:
		Foreign currency translation adjustment	$	(715)	$	(426)

Attributable to Henry Schein, Inc.:
	Foreign currency translation loss		$	(180,267)	$	(234,799)
	Unrealized loss from foreign currency hedging activities			(1,742)		(156)
	Unrealized investment gain (loss)			2		(6)
	Pension adjustment loss			(13,419)		(13,810)
		Accumulated other comprehensive loss	$	(195,426)	$	(248,771)

Total Accumulated other comprehensive loss			$	(219,056)	$	(267,792)

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

	Three Months Ended				Nine Months Ended
	September 28,		September 29,		September 28,		September 29,
	2019		2018		2019		2018
Net income	$	148,853	$	126,976	$	382,693	$	423,116

Foreign currency translation loss		(60,635)		(10,582)		(43,926)		(106,154)
Tax effect		-		-		-		-
Foreign currency translation loss		(60,635)		(10,582)		(43,926)		(106,154)

Unrealized gain (loss) from foreign currency hedging
activities		(1,685)		(406)		(2,037)		1,079
Tax effect		422		27		451		(405)
Unrealized gain (loss) from foreign currency hedging
activities		(1,263)		(379)		(1,586)		674

Unrealized investment gain (loss)		3		(1)		10		(2)
Tax effect		(1)		-		(2)		-
Unrealized investment gain (loss)		2		(1)		8		(2)

Pension adjustment gain		585		139		1,146		1,449
Tax effect		(185)		(23)		(314)		(393)
Pension adjustment gain		400		116		832		1,056
Comprehensive income	$	87,357	$	116,130	$	338,021	$	318,690

During the three months ended September 28, 2019 and September 29, 2018, we recognized, as a component of our comprehensive income, a foreign currency translation loss of $60.6 million and $10.6 million, respectively, due to changes in foreign exchange rates from the beginning of the period to the end of the period. During the nine months ended September 28, 2019 and September 29, 2018, we recognized, as a component of our comprehensive income, a foreign currency translation loss of $43.9 million and $106.2 million, respectively, due to changes in foreign exchange rates from the beginning of the period to the end of the period. Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income (loss). The foreign currency translation gain (loss) during the three and nine months ended September 28, 2019 and September 29, 2018 was primarily impacted by changes in foreign currency exchange rates of the Euro, Brazilian Real, British Pound and Australian Dollar.The following table summarizes our total comprehensive income, net of applicable taxes, as follows:

		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,
		2019		2018		2019		2018
Comprehensive income attributable to
	Henry Schein, Inc.	$	85,075	$	113,221	$	324,809	$	313,326
Comprehensive income attributable to
	noncontrolling interests		3,924		2,478		7,280		2,097
Comprehensive income (loss) attributable to
	Redeemable noncontrolling interests		(1,642)		431		5,932		3,267
Comprehensive income		$	87,357	$	116,130	$	338,021	$	318,690

Fair Value Measurements

9 Months Ended

Sep. 28, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 10 – Fair Value Measurements

ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC Topic 820”) provides a framework for measuring fair value in generally accepted accounting principles.

ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:

• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3— Inputs that are unobservable for the asset or liability.

The following section describes the valuation methodologies that we used to measure different financial instruments at fair value.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value.

Debt

The fair value of our debt, including bank credit lines, as of September 28, 2019 and December 29, 2018 was estimated at $1,089.3 million and $1,940.1 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

Derivative contracts

Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to intercompany loans and certain forecasted inventory purchase commitments with suppliers.

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy.

Redeemable noncontrolling interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value based on third-party valuations. The primary factor affecting the future value of redeemable noncontrolling interests is expected earnings and, if such earnings are not achieved, the value of the redeemable noncontrolling interests might be impacted. The noncontrolling interests subject to put options are adjusted to their estimated redemption amounts each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy. The details of the changes in Redeemable noncontrolling interests are presented in Note 8.

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 28, 2019 and December 29, 2018:

			September 28, 2019
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	5,620	$	-	$	5,620
		Total assets	$	-	$	5,620	$	-	$	5,620

Liabilities:
	Derivative contracts		$	-	$	3,629	$	-	$	3,629
		Total liabilities	$	-	$	3,629	$	-	$	3,629

Redeemable noncontrolling interests			$	-	$	-	$	283,325	$	283,325


			December 29, 2018
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	12,533	$	-	$	12,533
		Total assets	$	-	$	12,533	$	-	$	12,533

Liabilities:
	Derivative contracts		$	-	$	1,708	$	-	$	1,708
		Total liabilities	$	-	$	1,708	$	-	$	1,708

Redeemable noncontrolling interests			$	-	$	-	$	219,724	$	219,724

Business Acquisitions

9 Months Ended

Sep. 28, 2019

Business Acquisitions

Business Acquisitions

Note 11 – Business Acquisitions

Acquisitions

The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.

During the nine months ended September 28, 2019 we completed the following acquisitions:

On March 4, 2019, we announced that we acquired North American Rescue (“NAR”), a leading provider of survivability and casualty-care medical products to the defense and public-safety markets. NAR has annual sales of approximately $184 million. As of September 28, 2019, we have recorded $168.9 million of goodwill related to this acquisition.

On March 18, 2019, we announced that our Henry Schein One subsidiary acquired Lighthouse 360, a provider of easy-to-use dental practice management and patient communication software. Lighthouse 360 has annual sales of approximately $50 million. As of September 28, 2019, we have recorded $143.4 million of goodwill related to this acquisition.

We completed certain other acquisitions during the nine months ended September 28, 2019 which were immaterial to our financial statements individually and in the aggregate.

Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the nine months ended September 28, 2019 and September 29, 2018, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities.

Plans of Restructuring

9 Months Ended

Sep. 28, 2019

Restructuring and Related Activities [Abstract]

Plans of Restructuring

Note 12 – Plans of Restructuring

On July 9, 2018, we committed to an initiative to rationalize our operations and provide expense efficiencies. These actions have allowed us to execute on our plan to reduce our cost structure and fund new initiatives that are expected to drive future growth under our 2018 to 2020 strategic plan. This initiative has resulted in the elimination of approximately 4% of our workforce and the closing of certain facilities.

During the three and nine months ended September 28, 2019, we recorded restructuring (credits) costs of $(0.8) million and $15.8 million, respectively. The restructuring credits in the three months ended September 28, 2019 were attributable to a reduction in previously recorded estimated restructuring costs as of June 29, 2019. The total 2018 costs associated with the actions to complete this restructuring were $54.4 million from continuing operations, consisting primarily of severance costs. As of June 29, 2019, the restructuring activities under this initiative are complete and we do not expect to incur any additional restructuring charges for the remainder of 2019. The costs associated with this restructuring are included in a separate line item, “Restructuring costs” within our consolidated statements of income.

The following table shows the net amounts expensed and paid for restructuring costs that were incurred during the nine months ended September 28, 2019 and during our 2018 fiscal year and the remaining accrued balance of restructuring costs as of September 28, 2019, which is included in Accrued expenses: Other within our consolidated balance sheet:

			Facility
	Severance		Closing
	Costs		Costs		Other		Total
Balance, December 30, 2017	$	3,087	$	1,315	$	24	$	4,426
Provision		50,197		3,153		1,017		54,367
Payments and other adjustments		(23,320)		(2,865)		(883)		(27,068)
Balance, December 29, 2018	$	29,964	$	1,603	$	158	$	31,725
Provision		14,733		945		86		15,764
Payments		(26,313)		(1,575)		(110)		(27,998)
Balance, September 28, 2019	$	18,384	$	973	$	134	$	19,491

The following table shows, by reportable segment, the net amounts expensed and paid for restructuring costs that were incurred during the nine months ended September 28, 2019 and during our 2018 fiscal year and the remaining accrued balance of restructuring costs as of September 28, 2019:

			Technology and
	Health Care		Value-Added
	Distribution		Services		Total
Balance, December 30, 2017	$	4,426	$	-	$	4,426
Provision		50,824		3,543		54,367
Payments and other adjustments		(24,959)		(2,109)		(27,068)
Balance, December 29, 2018	$	30,291	$	1,434	$	31,725
Provision		14,966		798		15,764
Payments		(26,349)		(1,649)		(27,998)
Balance, September 28, 2019	$	18,908	$	583	$	19,491

Earnings Per Share

9 Months Ended

Sep. 28, 2019

Earnings Per Share [Abstract]

Earnings Per Share

Note 13 – Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

		Three Months Ended		Nine Months Ended
		September 28,	September 29,	September 28,	September 29,
		2019	2018	2019	2018
Basic		147,136	152,533	148,603	152,970
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,439	1,081	1,317	1,012
	Diluted	148,575	153,614	149,920	153,982

Income Taxes

9 Months Ended

Sep. 28, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 14 – Income Taxes

For the nine months ended September 28, 2019, our effective tax rate was 23.9% compared to 21.8% for the prior year period. The difference between our effective tax rates and the federal statutory tax rate for the nine months ended September 28, 2019 primarily relates to state and foreign income taxes and interest expense. The difference between our effective tax rates and the federal statutory tax rate for the nine months ended September 29, 2018 primarily relates to a provisional transition tax benefit of $10 million related to the Tax Act, as well as state and foreign income taxes and interest expense.

On December 22, 2017, the U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes to the U.S. tax code including, but not limited to, the reduction of the corporate tax rate from 35% to 21%, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. The Tax Act also included provisions to tax global intangible low-taxed income (“GILTI”), a beneficial tax rate foreign Derived Intangible Income (“FDII”), a base erosion and anti-abuse tax (“BEAT”) that imposes tax on certain foreign related-party payments, and IRC Section 163(j) interest limitation (Interest Limitation). We became subject to the GILTI, FDII, BEAT and Interest Limitation provisions effective January 1, 2018.

The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. For the BEAT, FDII and Interest Limitation computations, we have not recorded an estimate in our effective tax rate for the nine months ended September 28, 2019 because we have concluded that these provisions of the Tax Act will not apply to us in 2019.

The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets, as of September 28, 2019 was approximately $107.6 million, of which $86.5 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our consolidated statement of income.

The total amounts of interest and penalties, which are classified as a component of the provision for income taxes and included in “Other liabilities”, were approximately $18.3 million and $0, respectively, as of September 28, 2019.

The tax years subject to examination by major tax jurisdictions include the years 2012 and forward by the U.S. Internal Revenue Service (“IRS”), as well as the years 2008 and forward for certain states and certain foreign jurisdictions. During the quarter ended December 31, 2016 we filed a Mutual Agreement Procedure request with the IRS for assistance from the U.S. Competent Authority for an open Transfer Pricing issue which resulted in a partial settlement during the quarter ended December 30, 2017. We received a 30 Day Letter from the IRS during the quarter ended April 1, 2017 for the remaining open audit issues for the years 2012 and 2013. We filed a Protest with the Appellate Division regarding these issues during the second quarter of 2017. We had an initial Appeals Conference during the third quarter of 2018, of which we are awaiting a final settlement. During the quarter ended December 29, 2018, we submitted the first draft of our proposed Advanced Pricing Agreement covering tax years 2014-2024 to the IRS in which Henry Schein, Inc. and the IRS would agree on an appropriate transfer pricing methodology. We have provided all necessary documentation to the Appellate Division and the Advance Pricing and Mutual Agreement Program to date and are waiting for responses.

Derivatives and Hedging Activities

9 Months Ended

Sep. 28, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives and Hedging Activities

Note 15 – Derivatives and Hedging Activities

We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC Topic 815 have been omitted.

Stock-Based Compensation

9 Months Ended

Sep. 28, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

Note 16 – Stock-Based Compensation

Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $13.3 million ($10.2 million after-tax) and $33.1 million ($25.2 million after-tax) for the three and nine months ended September 28, 2019, respectively, and $9.5 million ($7.6 million after-tax) and $30.6 million ($23.4 million after-tax) for the three and nine months ended September 29, 2018, respectively.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2013 Stock Incentive Plan, as amended, and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Prior to March 2009, awards under the Plans principally included a combination of at-the-money stock options and restricted stock/units. Since March 2009, equity-based awards have been granted solely in the form of restricted stock/units, with the exception of providing stock options to employees pursuant to certain pre-existing contractual obligations.

Grants of restricted stock/units are stock-based awards granted to recipients with specified vesting provisions. In the case of restricted stock, common stock is delivered on the date of grant, subject to vesting conditions. In the case of restricted stock units, common stock is generally delivered on or following satisfaction of vesting conditions. We issue restricted stock/units that vest solely based on the recipient’s continued service over time (primarily four-year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily 12-month cliff vesting) and restricted stock/units that vest based on our achieving specified performance measurements and the recipient’s continued service over time (primarily three-year cliff vesting).

With respect to time-based restricted stock/units, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock/units, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted stock/units based on our closing stock price at time of grant.

The Plans provide for adjustments to the performance-based restricted stock/units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations and foreign exchange fluctuations. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.

As a result of the Separation, the number of our unvested equity-based awards from previous grants to our remaining employees under our Long-term Incentive Program was increased in accordance with the provisions in the Plans. This was based on a factor of approximately 1.2633, corresponding with a decrease in our price per share.

Total unrecognized compensation cost related to unvested awards as of September 28, 2019 was $97.5 million, which is expected to be recognized over a weighted-average period of approximately 2.2 years.

The following table summarizes stock option activity under the Plans during the nine months ended September 28, 2019:

				Weighted
				Average
		Weighted		Remaining
		Average		Contractual	Aggregate
		Exercise		Life in	Intrinsic
	Shares	Price		Years	Value
Outstanding at beginning of period	3	$	13.63
Granted	-		-
Exercised	(3)		13.63
Forfeited	-		-
Outstanding at end of period	-	$	-	-	$	-

Options exercisable at end of period	-	$	-	-	$	-

The following tables summarize the activity of our unvested restricted stock/units for the nine months ended September 28, 2019:

	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,513	$	57.94
Granted	449		59.47
Vested	(338)		55.57
Forfeited	(204)		60.39
Outstanding at end of period	1,420	$	58.66	$	62.58

	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,163	$	40.26
Granted	656		60.04
Vested	(185)		66.52
Forfeited	(155)		61.37
Outstanding at end of period	1,479	$	61.41	$	62.58

Supplemental Cash Flow Information

9 Months Ended

Sep. 28, 2019

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Note 17 – Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

	Nine Months Ended
	September 28,		September 29,
	2019		2018
Interest	$	45,543	$	49,959
Income taxes		138,068		197,943

During the nine months ended September 28, 2019 and September 29, 2018, we had a $2.0 million non-cash net unrealized loss related to foreign currency hedging activities and a $1.1 million non-cash net unrealized gain related to foreign currency hedging activities, respectively.

Legal Proceedings

9 Months Ended

Sep. 28, 2019

Commitments and Contingencies Disclosure [Abstract]

Legal Proceedings

Note 18 – Legal Proceedings

Beginning in January 2016, purported class action complaints were filed against Patterson Companies, Inc. (“Patterson”), Benco Dental Supply Co. (“Benco”) and Henry Schein, Inc. Although there were factual and legal variations among these complaints, each of these complaints alleges, among other things, that defendants conspired to fix prices, allocate customers and foreclose competitors by boycotting manufacturers, state dental associations and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, “putative class representatives”) in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and non-party Burkhart Dental Supply Company, Inc. (“Burkhart”) not to compete on price. The consolidated class action complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On September 28, 2018, the parties executed a settlement agreement that proposes, subject to court approval, a full and final settlement of the lawsuit on a classwide basis. Subject to certain exceptions, the settlement class consists of all persons or entities that purchased dental products directly from Henry Schein, Patterson, Benco, Burkhart, or any combination thereof, during the period August 31, 2008 through and including March 31, 2016. As a result, in our third quarter of fiscal 2018, we recorded a charge of $38.5 million, which was paid into a settlement fund in January 2019. On June 25, 2019, the district court granted final approval to the settlement, and entered final judgment dismissing the case. On July 16, 2019, Dr. William Roe, an unnamed class member that had objected to the settlement, filed a notice of appeal appealing the district court’s Final Judgment and Order Granting Motion for Final Approval of Class Settlement. On October 8, 2019, the class plaintiffs and the objector filed notice indicating that they had reached a settlement concerning the objection, which, once approved by the court, would resolve the objection. On October 24, 2019 the court approved the agreement between the objector and the plaintiffs.

On August 31, 2012, Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act.

Archer alleges aconspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson and Benco as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer seeks damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017, Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint.

On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit has not ruled on that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020. We intend to defend ourselves vigorously against this action.

On August 17, 2017, IQ Dental Supply, Inc. (“IQ Dental”) filed a complaint in the U.S. District Court for the Eastern District of New York, entitled IQ Dental Supply, Inc. v. Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company, Case No. 2:17-cv-4834. Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental (“SourceOne”). SourceOne had previously brought an antitrust lawsuit against Henry Schein, Patterson and Benco, which Henry Schein settled in the second quarter of 2017 and which is described in our prior filings with the SEC.

IQ Dental alleges, among other things, that defendants conspired to suppress competition from IQ Dental and SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017, the District Court granted the defendants’ motion to dismiss. On January 19, 2018, IQ Dental appealed the District Court’s order. On May 10, 2019, the U.S. Court of Appeals for the Second Circuit affirmed in part and reversed in part the District Court’s dismissal of the Complaint, holding that IQ Dental lacks antitrust standing to challenge the alleged boycott of SourceOne and state dental associations, but that it has standing to challenge injury related to the alleged direct boycott of its business. On June 29, 2019, the Second Circuit denied IQ Dental’s petition for rehearing or rehearing en banc. Proceedings in the District Court are ongoing. We intend to defend ourselves vigorously against this action.

On February 12, 2018, the United States Federal Trade Commission (“FTC”) filed a complaint against Benco Dental Supply Co., Henry Schein, Inc. and Patterson Companies, Inc. The FTC alleges, among other things, that defendants violated U.S. antitrust laws by conspiring, and entering into an agreement, to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners. The FTC alleges that defendants conspired in violation of Section 5 of the FTC Act. The complaint seeks equitable relief only and does not seek monetary damages. We deny the allegation that we conspired to refuse to provide discounts to or otherwise serve dental buying groups and intend to defend ourselves vigorously against this action. A hearing before an administrative law judge began on October 16, 2018 and the hearing record was closed on February 21, 2019. On October 7, 2019, the administrative law judge issued his Initial Decision, finding in relevant part that the “evidence fails to prove a conspiracy involving Schein,” and dismissing the Complaint as to Schein. The Initial Decision will become the decision of the Commission on or about November 7, 2019 unless the Commission places the case on its own docket for review or stays the effective date of the decision. We believe this matter will not have a material adverse effect on our consolidated financial position, liquidity or results of operations.

On March 7, 2018, Joseph Salkowitz, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Stanley M. Bergman and Steven Paladino in the U.S. District Court for the Eastern District of New York, Case No. 1:18-cv-01428. The complaint sought to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased Henry Schein securities from March 7, 2013 through February 12, 2018 (the “Class Period”). The complaint alleged, among other things, that the defendants had made materially false and misleading statements about Henry Schein’s business, operations and prospects during the Class Period, including matters relating to the issues in the antitrust class action and the FTC action described above, thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities. The complaint sought unspecified monetary damages and a jury trial. Pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), the court appointed lead plaintiff and lead counsel on June 22, 2018 and recaptioned the putative class action as In re Henry Schein, Inc. Securities Litigation, under the same case number. Lead plaintiff filed a consolidated class action complaint on September 14, 2018. The consolidated class action complaint asserts similar claims against the same defendants (plus Timothy Sullivan) on behalf of the same putative class of purchasers during the Class Period. It alleges that Henry Schein’s stock price was inflated during that period because Henry Schein had misleadingly portrayed its dental-distribution business “as successfully producing excellent profits while operating in a highly competitive environment” even though, “in reality, [Henry Schein] had engaged for years in collusive and anticompetitive practices in order to maintain Schein’s margins, profits, and market share.” The complaint alleges that the stock price started to fall from August 8, 2017, when the company announced below-expected financial performance that allegedly “revealed that Schein’s poor results were a product of abandoning prior attempts to inflate sales volume and margins through anticompetitive collusion,” through February 13, 2018, after the FTC filed a complaint against Benco, Henry Schein and Patterson alleging that they violated U.S. antitrust laws. The complaint alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 and Section 20(a) of the Exchange Act. On September 27, 2019, the court issued a decision partially granting and partially denying defendants’ motion to dismiss the securities action. The court dismissed all claims against Messrs. Bergman and Paladino as well as the Section 10(b) claim against Henry Schein to the extent that that claim relied on the Company’s financial results and margins to allege a material misstatement or omission, and on the Company’s August 8, 2017 disclosure to allege loss causation. The court otherwise denied the motion as to Henry Schein and Mr. Sullivan. We intend to defend ourselves vigorously against this action. Henry Schein has also received a request under 8 Del. C. § 220 to inspect corporate books and records relating to the issues raised in the securities class action and the antitrust matters discussed above.

On May 3, 2018, a purported class action complaint, Marion Diagnostic Center, LLC, et al. v. Becton, Dickinson, and Co., et al., Case No. 3:18-cv-010509, was filed in the U.S. District Court for the Southern District of Illinois against

Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton DistributorCo-Conspirators. The complaint alleges that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels. The named plaintiffs seek to represent three separate classes consisting of all health care providers that purchased (i) Becton’s conventional syringes, (ii) Becton’s safety syringes, or (iii) Becton’s safety catheters directly from Becton, Premier, Vizient, Cardinal, O&M or Henry Schein on or after May 3, 2014. The complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, treble damages, reasonable attorneys’ fees and costs and expenses, and pre-judgment and post-judgment interest. On June 15, 2018, an amended complaint was filed asserting the same allegations against the same parties and adding McKesson Medical-Surgical, Inc. as a defendant. On November 30, 2018, the District Court granted defendants’ motion to dismiss and entered a final judgment, dismissing plaintiffs’ complaint with prejudice. On December 27, 2018, plaintiffs appealed the District Court’s decision to the Seventh Circuit Court of Appeals. The parties argued the appeal on September 27, 2019 and are currently awaiting the Seventh Circuit’s ruling.

On May 29, 2018, an amended complaint was filed in the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants. Summit County alleges that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, will establish and donate $1 million to a Pain Management Education Foundation dedicated to making grants to programs within Summit County focused on (I) supporting and aggregating research around best practices for pain management, including the prescription of opioids and alternatives: (II) educating dentists and physicians, clinical associates, patients and patient networks on those best practices along with the risks of opioid addiction and alternative pain management treatment options for key indications; and ‎(III) offering grants to develop and offer training to dentists and physicians or other qualified professionals to qualify a practitioner for a waiver to prescribe or dispense buprenorphine medications. Henry Schein will pay $250,000 of Summit County’s expenses.

In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have currently been named as a defendant in multiple lawsuits (currently less than one-hundred (100)), which allege claims similar to those alleged in the County of Summit Action. None of these other cases have been set for trial. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. Of Henry Schein’s 2018 revenue of $9.4 billion from continuing operations, sales of opioids represented less than one-tenth of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

On October 9, 2018, a purported class action complaint entitled Kramer v. Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and Unnamed Co-Conspirators, was filed in the U.S. District Court for the Northern District of California. The complaint alleges that members of the proposed class, comprised of purchasers of dental services from dental practices in California, suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged California dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the California class purchasing dental services. Subject to certain exclusions, the complaint defines the class as “all persons residing in California purchasing and/or reimbursing for dental services from California dental practices on or after August 31, 2012.” The complaint alleges violations of California antitrust laws, including the Cartwright Act (Cal.

Bus. and Prof. Code § 16720) and the Unfair Competition Act (Cal. Bus. and Prof. Code § 17200), and seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. On December 7, 2018, an amended complaint was filed asserting the same claims against the same parties. On June 28, 2019, the court granted Defendants’ motions to dismiss with leave to amend. The parties subsequently stipulated to dismissal of the action with prejudice, pursuant to a settlement in which Henry Schein agreed to pay the plaintiff a de minimis amount. The court entered the stipulation of dismissal with prejudice and terminated the case on August 2, 2019.

On January 29, 2019, a purported class action complaint was filed by R. Lawrence Hatchett, M.D. against Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators in the U.S. District Court for the Southern District of Illinois. The complaint alleges that members of the proposed class suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged Illinois dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the class. Subject to certain exclusions, the complaint defines the class as “all persons residing in Illinois purchasing and/or reimbursing for dental care provided by independent Illinois dental practices purchasing dental supplies from the defendants, or purchasing from buying groups purchasing these supplies from the defendants, on or after January 29, 2015.” The complaint alleges violations of the Illinois Antitrust Act, 740 Ill. Comp. Stat. §§ 10/3(2), 10/7(2), and seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. We intend to defend ourselves vigorously against this action.

On September 30, 2019, City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. We intend to defend ourselves vigorously against this action.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of September 28, 2019, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Subsequent Events

9 Months Ended

Sep. 28, 2019

Subsequent Events

Subsequent Events

Note 19 – Subsequent Events

On October 1, 2019, the Company sold an equity investment in Hu-Friedy Mfg. Co., LLC, a manufacturer of dental instruments and infection prevention solutions. Our investment was non-controlling, we were not involved in running the business and had no representation on the board of directors. We estimate that in the fourth quarter of 2019 we will record a pretax gain from this sale in the range of $225 million to $275 million. Our final calculation of the gain will take into account the accounting treatment of contingent consideration associated with the transaction and the appropriate income tax treatment.

Critical Accounting Policies and Accounting Pronouncements Adopted (Policies)	9 Months Ended
	Sep. 28, 2019
Critical Accounting Policies and Estimates and Accounting Pronouncements Adopted
Leases	Leases We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in Property and equipment, Current maturities of long-term debt, and Long-term debt in our consolidated balance sheet. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Leases with a lease term of 12 months or less are not capitalized. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Short-term Leases	Leases with a lease term of 12 months or less are not capitalized.
Separation of Lease and Nonlease Components	We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Accounting Pronouncements Adopted	Accounting Pronouncements Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02 “Leases (Topic 842)” related to leases requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most significant among the changes in the standard is the recognition of ROU assets and lease liabilities by lessors for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted the standard on December 30, 2018 using a modified retrospective approach utilizing a transition relief expedient method whereby we continue to apply existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative-effect adjustment in the period of adoption, rather than in the earliest period presented without adjusting historical financial statements. We elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Information related to leases as of September 28, 2019 is presented under Topic 842, while prior period amounts are not adjusted and continue to be reported under legacy guidance in Topic 840. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while our accounting for finance leases remained substantially unchanged. Adoption of the new standard resulted in the recording of additional net operating lease assets of $259.9 million and operating lease liabilities of $267.3 million, and a decrease of $1.1 million and $8.5 million in prepaid rent and deferred rent liabilities, respectively. The standard did not materially impact our consolidated net income and had no impact on cash flows. In February 2018, the FASB issued ASU No. 2018-02, "Treatment of Stranded Tax Effects in Accumulated Other Comprehensive Income Resulting From the Tax Cuts and Jobs Act of 2017," which allows the reclassification from accumulated comprehensive income to retained earnings the income tax effects resulting from the Tax Cuts and Jobs Act of 2017 (the “Tax Act”). This ASU is effective for interim and annual reporting periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements. In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging” (Topic 815), which simplified the requirements for hedge accounting, more closely aligns hedge accounting risk with risk management activities and increases transparency of the scope and results of hedging activities. This ASU amends the presentation and disclosure requirements and changes how we can assess the effectiveness of our hedging relationships. This ASU will make more financial and nonfinancial hedging strategies eligible for hedge accounting. This ASU is effective for interim and annual reporting periods beginning after December 15, 2018. The adoption of this ASU did not have a material impact on our consolidated financial statements.
Income Taxes	On December 22, 2017, the U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes to the U.S. tax code including, but not limited to, the reduction of the corporate tax rate from 35% to 21%, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. The Tax Act also included provisions to tax global intangible low-taxed income (“GILTI”), a beneficial tax rate foreign Derived Intangible Income (“FDII”), a base erosion and anti-abuse tax (“BEAT”) that imposes tax on certain foreign related-party payments, and IRC Section 163(j) interest limitation (Interest Limitation). We became subject to the GILTI, FDII, BEAT and Interest Limitation provisions effective January 1, 2018. The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. For the BEAT, FDII and Interest Limitation computations, we have not recorded an estimate in our effective tax rate for the nine months ended September 28, 2019 because we have concluded that these provisions of the Tax Act will not apply to us in 2019.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

+ Details

Discontinued Operations (Tables)

9 Months Ended

Sep. 28, 2019

Discontinued Operations

Summarized financial information for discontinued operations

	Three Months Ended				Nine Months Ended
	September 28,		September 29,		September 28,		September 29,
	2019		2018		2019		2018

Net sales	$	-	$	924,114	$	319,522	$	2,881,747
Gross profit		-		166,201		59,425		525,408
Operating income (loss)		(1,063)		42,657		(8,588)		130,800
Income tax expense (benefit)		(6,704)		12,767		(2,023)		37,430
Income (loss) from discontinued operations		5,641		30,729		(5,576)		97,561
Net (income) loss attributable to noncontrolling interests		-		(21)		366		(7,593)
Net income (loss) from discontinued operations
attributable to Henry Schein, Inc.		5,641		30,708		(5,210)		89,968

			February 7,		December 29,
			2019		2018
			(unaudited)		(unaudited)

Cash and cash equivalents			$	6,815	$	23,324
Accounts receivable, net				432,812		434,935
Inventories, net				536,637		555,230
Prepaid expenses and other				120,546		69,525
		Total current assets of discontinued operations		1,096,810		1,083,014
Property and equipment, net				69,790		68,177
Operating lease right-of-use asset, net				57,012		-
Goodwill				742,931		739,266
Other intangibles, net				205,793		208,213
Investments and other				120,518		118,003
		Total long-term assets of discontinued operations		1,196,044		1,133,659
Total assets of discontinued operations			$	2,292,854	$	2,216,673

Accounts payable			$	316,162	$	441,453
Current maturities of long-term debt				657		675
Operating lease liabilities				18,951		-
Accrued expenses:
	Payroll and related			36,847		36,888
	Taxes			24,060		17,552
	Other			80,400		81,039
		Total current liabilities of discontinued operations		477,077		577,607
Long-term debt				1,176,105		23,529
Deferred income taxes				17,019		4,352
Operating lease liabilities				38,668		-
Other liabilities				29,209		34,572
		Total long-term liabilities of discontinued operations		1,261,001		62,453
Total liabilities of discontinued operations			$	1,738,078	$	640,060
Redeemable noncontrolling interests			$	28,270	$	92,432

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 28, 2019

Revenue from Contracts with Customers

Disaggregation of Revenue

			Three Months Ended						Nine Months Ended
			September 28, 2019						September 28, 2019
			North America		International		Global		North America		International		Global
Revenues:
	Health care distribution
		Dental	$	951,796	$	594,188	$	1,545,984	$	2,850,762	$	1,843,041	$	4,693,803
		Medical		784,349		19,360		803,709		2,125,002		59,925		2,184,927
		Total health care distribution		1,736,145		613,548		2,349,693		4,975,764		1,902,966		6,878,730
	Technology and value-added services			120,197		17,134		137,331		327,618		50,273		377,891
	Total excluding Corporate TSA revenues ⁽¹⁾			1,856,342		630,682		2,487,024		5,303,382		1,953,239		7,256,621
	Corporate TSA revenues ⁽¹⁾			1,077		20,666		21,743		4,098		56,143		60,241
		Total revenues	$	1,857,419	$	651,348	$	2,508,767	$	5,307,480	$	2,009,382	$	7,316,862

			Three Months Ended						Nine Months Ended
			September 29, 2018						September 29, 2018
			North America		International		Global		North America		International		Global
Revenues:
	Health care distribution
		Dental	$	951,199	$	563,126	$	1,514,325	$	2,830,384	$	1,844,150	$	4,674,534
		Medical		702,758		19,184		721,942		1,915,944		60,423		1,976,367
		Total health care distribution		1,653,957		582,310		2,236,267		4,746,328		1,904,573		6,650,901
	Technology and value-added services			103,955		15,343		119,298		245,761		48,385		294,146
	Total excluding Corporate TSA revenues ⁽¹⁾			1,757,912		597,653		2,355,565		4,992,089		1,952,958		6,945,047
	Corporate TSA revenues ⁽¹⁾			-		-		-		-		-		-
		Total revenues	$	1,757,912	$	597,653	$	2,355,565	$	4,992,089	$	1,952,958	$	6,945,047


(1)	Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

Segment Data (Tables)

9 Months Ended

Sep. 28, 2019

Segment Data

Business segment information

			Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,
			2019		2018		2019		2018
Net Sales:
	Health care distribution ^(1):
		Dental	$	1,545,984	$	1,514,325	$	4,693,803	$	4,674,534
		Medical		803,709		721,942		2,184,927		1,976,367
		Total health care distribution		2,349,693		2,236,267		6,878,730		6,650,901
	Technology and value-added services ⁽²⁾			137,331		119,298		377,891		294,146
		Total excluding Corporate TSA revenue		2,487,024		2,355,565		7,256,621		6,945,047
	Corporate TSA revenues ⁽³⁾			21,743		-		60,241		-
		Total	$	2,508,767	$	2,355,565	$	7,316,862	$	6,945,047


(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.
(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.

			Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,
			2019		2018		2019		2018
Operating Income:
	Health care distribution		$	149,497	$	91,306	$	429,026	$	358,978
	Technology and value-added services			37,701		31,963		92,901		83,639
		Total	$	187,198	$	123,269	$	521,927	$	442,617

Debt (Tables)

9 Months Ended

Sep. 28, 2019

Debt

Bank credit lines

	September 28,		December 29,
	2019		2018
Revolving credit agreement	$	75,000	$	175,000
Other short-term bank credit lines		32,841		376,458
Committed loan associated with Animal Health Spin-off		-		400,000
Total	$	107,841	$	951,458

Long-term debt

		September 28,		December 29,
		2019		2018
Private placement facilities		$	621,217	$	628,189
U.S. trade accounts receivable securitization			350,000		350,000
Various collateralized and uncollateralized loans payable with interest
	in varying installments through 2024 at interest rates
	ranging from 2.56% to 10.5% at September 28,2019 and
	ranging from 2.61% to 4.17% at December 29, 2018		5,995		6,491
Finance lease obligations payable through 2029 with interest rates
	ranging from 1.64% to 19.13% at September 28,2019 and
	ranging from 1.45% to 6.00% at December 29, 2018		4,205		3,944
Total			981,417		988,624
Less current maturities			(109,188)		(8,280)
	Total long-term debt	$	872,229	$	980,344

Private placement facilities

	Amount of
	Borrowing		Borrowing
Date of Borrowing	Outstanding		Rate		Due Date
September 2, 2010	$	100,000	3.79	%	September 2, 2020
January 20, 2012		50,000	3.45		January 20, 2024
January 20, 2012		21,429	3.09		January 20, 2022
December 24, 2012		50,000	3.00		December 24, 2024
June 2, 2014		100,000	3.19		June 2, 2021
June 16, 2017		100,000	3.42		June 16, 2027
September 15, 2017		100,000	3.52		September 15, 2029
January 2, 2018		100,000	3.32		January 2, 2028
Less: Deferred debt issuance costs		(212)
	$	621,217


(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Leases (Tables)

9 Months Ended

Sep. 28, 2019

Leases

Components of lease expense, supplemental cash flow, and supplemental balance sheet information

		Three Months Ended		Nine Months Ended
		September 28,		September 28,
		2019		2019
Operating lease cost:⁽¹⁾		$	21,840	$	68,273
Finance lease cost:
	Amortization of right-of-use assets		290		798
	Interest on lease liabilities		31		88
Total finance lease cost		$	321	$	886


(1)	Includes variable lease expenses.

Supplemental balance sheet information related to leases is as follows:
		September 28,
		2019
Operating Leases:
Operating lease right-of-use assets		$	240,126

Current operating lease liabilities			67,374
Non-current operating lease liabilities			182,505
	Total operating lease liabilities	$	249,879

Finance Leases:
Property and equipment, at cost		$	10,826
Accumulated depreciation			(6,115)
Property and equipment, net of accumulated depreciation		$	4,711

Current maturities of long-term debt		$	1,092
Long-term debt			3,113
	Total finance lease liabilities	$	4,205

Weighted Average Remaining Lease Term in Years:
	Operating leases		5.5
	Finance leases		6.1

Weighted Average Discount Rate:
	Operating leases		3.4	%
	Finance leases		2.2	%

Supplemental cash flow information related to leases is as follows:
		September 28,
		2019
Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for operating leases	$	60,275
	Operating cash flows for finance leases		67
	Financing cash flows for finance leases		862
Right-of-use assets obtained in exchange for lease obligations:
	Operating leases ⁽¹⁾	$	281,373
	Finance leases		1,149


(1)	Includes leases that commenced during the nine months ended September 28, 2019, as well as balances related to leases in existence as of the date of the adoption of Topic 842.

Maturities of operating lease liabilities

Maturities of lease liabilities are as follows:
		September 28,
		2019
		Operating		Finance
		Leases		Leases
2019 (excluding the nine months ended September 28, 2019)	$	21,149	$	453
2020		69,052		1,135
2021		54,082		846
2022		37,886		434
2023		26,051		295
Thereafter		67,075		1,372
Total future lease payments		275,295		4,535
Less imputed interest		(25,416)		(330)
Total	$	249,879	$	4,205

Maturities of finance lease liabilities

Maturities of lease liabilities are as follows:
		September 28,
		2019
		Operating		Finance
		Leases		Leases
2019 (excluding the nine months ended September 28, 2019)	$	21,149	$	453
2020		69,052		1,135
2021		54,082		846
2022		37,886		434
2023		26,051		295
Thereafter		67,075		1,372
Total future lease payments		275,295		4,535
Less imputed interest		(25,416)		(330)
Total	$	249,879	$	4,205

Operating leases

		Operating		Finance
		Leases		Leases
2019	$	62,535	$	976
2020		47,686		801
2021		34,633		501
2022		25,626		305
2023		19,560		283
Thereafter		62,918		1,430
Total minimum lease payments	$	252,958		4,296
Less imputed interest (Capital leases only)				(352)
Total present value of minimum lease payments			$	3,944

Finance leases

		Operating		Finance
		Leases		Leases
2019	$	62,535	$	976
2020		47,686		801
2021		34,633		501
2022		25,626		305
2023		19,560		283
Thereafter		62,918		1,430
Total minimum lease payments	$	252,958		4,296
Less imputed interest (Capital leases only)				(352)
Total present value of minimum lease payments			$	3,944

Redeemable Noncontrolling Interests (Tables)

9 Months Ended

Sep. 28, 2019

Redeemable Noncontrolling Interests

Change in fair value of redeemable noncontrolling interests

		September 28,		December 29,
		2019		2018
Balance, beginning of period		$	219,724	$	465,585
Decrease in redeemable noncontrolling interests due to
	redemptions		(2,270)		(287,767)
Increase in redeemable noncontrolling interests due to business
	acquisitions		73,975		4,655
Net income attributable to redeemable noncontrolling interests			10,618		15,327
Dividends declared			(7,943)		(8,206)
Effect of foreign currency translation loss attributable to
	redeemable noncontrolling interests		(4,912)		(11,330)
Change in fair value of redeemable securities			(5,867)		41,460
Balance, end of period		$	283,325	$	219,724

Comprehensive Income (Tables)

9 Months Ended

Sep. 28, 2019

Comprehensive Income

Accumulated other comprehensive income, net of applicable taxes

			September 28,		December 29,
			2019		2018
Attributable to Redeemable noncontrolling interests:
		Foreign currency translation adjustment	$	(22,915)	$	(18,595)

Attributable to noncontrolling interests:
		Foreign currency translation adjustment	$	(715)	$	(426)

Attributable to Henry Schein, Inc.:
	Foreign currency translation loss		$	(180,267)	$	(234,799)
	Unrealized loss from foreign currency hedging activities			(1,742)		(156)
	Unrealized investment gain (loss)			2		(6)
	Pension adjustment loss			(13,419)		(13,810)
		Accumulated other comprehensive loss	$	(195,426)	$	(248,771)

Total Accumulated other comprehensive loss			$	(219,056)	$	(267,792)

Components of comprehensive income, net of applicable taxes

	Three Months Ended				Nine Months Ended
	September 28,		September 29,		September 28,		September 29,
	2019		2018		2019		2018
Net income	$	148,853	$	126,976	$	382,693	$	423,116

Foreign currency translation loss		(60,635)		(10,582)		(43,926)		(106,154)
Tax effect		-		-		-		-
Foreign currency translation loss		(60,635)		(10,582)		(43,926)		(106,154)

Unrealized gain (loss) from foreign currency hedging
activities		(1,685)		(406)		(2,037)		1,079
Tax effect		422		27		451		(405)
Unrealized gain (loss) from foreign currency hedging
activities		(1,263)		(379)		(1,586)		674

Unrealized investment gain (loss)		3		(1)		10		(2)
Tax effect		(1)		-		(2)		-
Unrealized investment gain (loss)		2		(1)		8		(2)

Pension adjustment gain		585		139		1,146		1,449
Tax effect		(185)		(23)		(314)		(393)
Pension adjustment gain		400		116		832		1,056
Comprehensive income	$	87,357	$	116,130	$	338,021	$	318,690

Total comprehensive income, net of applicable taxes

		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,
		2019		2018		2019		2018
Comprehensive income attributable to
	Henry Schein, Inc.	$	85,075	$	113,221	$	324,809	$	313,326
Comprehensive income attributable to
	noncontrolling interests		3,924		2,478		7,280		2,097
Comprehensive income (loss) attributable to
	Redeemable noncontrolling interests		(1,642)		431		5,932		3,267
Comprehensive income		$	87,357	$	116,130	$	338,021	$	318,690

Fair Value Measurements (Tables)

9 Months Ended

Sep. 28, 2019

Fair Value Disclosures [Abstract]

Fair value - assets and liabilities measured and recognized on a recurring basis

			September 28, 2019
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	5,620	$	-	$	5,620
		Total assets	$	-	$	5,620	$	-	$	5,620

Liabilities:
	Derivative contracts		$	-	$	3,629	$	-	$	3,629
		Total liabilities	$	-	$	3,629	$	-	$	3,629

Redeemable noncontrolling interests			$	-	$	-	$	283,325	$	283,325


			December 29, 2018
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	-	$	12,533	$	-	$	12,533
		Total assets	$	-	$	12,533	$	-	$	12,533

Liabilities:
	Derivative contracts		$	-	$	1,708	$	-	$	1,708
		Total liabilities	$	-	$	1,708	$	-	$	1,708

Redeemable noncontrolling interests			$	-	$	-	$	219,724	$	219,724

Plans of Restructuring (Tables)

9 Months Ended

Sep. 28, 2019

Restructuring and Related Activities [Abstract]

Schedule of restructuring reserve by type of cost

			Facility
	Severance		Closing
	Costs		Costs		Other		Total
Balance, December 30, 2017	$	3,087	$	1,315	$	24	$	4,426
Provision		50,197		3,153		1,017		54,367
Payments and other adjustments		(23,320)		(2,865)		(883)		(27,068)
Balance, December 29, 2018	$	29,964	$	1,603	$	158	$	31,725
Provision		14,733		945		86		15,764
Payments		(26,313)		(1,575)		(110)		(27,998)
Balance, September 28, 2019	$	18,384	$	973	$	134	$	19,491

Schedule of restructuring reserve by segment

			Technology and
	Health Care		Value-Added
	Distribution		Services		Total
Balance, December 30, 2017	$	4,426	$	-	$	4,426
Provision		50,824		3,543		54,367
Payments and other adjustments		(24,959)		(2,109)		(27,068)
Balance, December 29, 2018	$	30,291	$	1,434	$	31,725
Provision		14,966		798		15,764
Payments		(26,349)		(1,649)		(27,998)
Balance, September 28, 2019	$	18,908	$	583	$	19,491

Earnings Per Share (Tables)

9 Months Ended

Sep. 28, 2019

Earnings Per Share [Abstract]

Reconciliation of basic and diluted shares used to calculate earnings per share

		Three Months Ended		Nine Months Ended
		September 28,	September 29,	September 28,	September 29,
		2019	2018	2019	2018
Basic		147,136	152,533	148,603	152,970
Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,439	1,081	1,317	1,012
	Diluted	148,575	153,614	149,920	153,982

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 28, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of the stock option activity under the plans

				Weighted
				Average
		Weighted		Remaining
		Average		Contractual	Aggregate
		Exercise		Life in	Intrinsic
	Shares	Price		Years	Value
Outstanding at beginning of period	3	$	13.63
Granted	-		-
Exercised	(3)		13.63
Forfeited	-		-
Outstanding at end of period	-	$	-	-	$	-

Options exercisable at end of period	-	$	-	-	$	-

Status of non-vested restricted shares/units

	Time-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,513	$	57.94
Granted	449		59.47
Vested	(338)		55.57
Forfeited	(204)		60.39
Outstanding at end of period	1,420	$	58.66	$	62.58

	Performance-Based Restricted Stock/Units
		Weighted Average
		Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,163	$	40.26
Granted	656		60.04
Vested	(185)		66.52
Forfeited	(155)		61.37
Outstanding at end of period	1,479	$	61.41	$	62.58

Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 28, 2019

Supplemental Cash Flow Elements [Abstract]

Cash paid for interest and income taxes

	Nine Months Ended
	September 28,		September 29,
	2019		2018
Interest	$	45,543	$	49,959
Income taxes		138,068		197,943

Basis of Presentation - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2019	Dec. 29, 2018
Discontinued Operation, Name	Henry Schein Animal Health Business
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity, Consolidated, Assets, Pledged	$ 419	$ 422
Variable Interest Entity, Consolidated, Liabilities, Recourse	$ 350	$ 350

Discontinued Operations Summarized financial information for our discontinued operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018	Feb. 07, 2019	Dec. 29, 2018	Dec. 30, 2017
Summarized financial information for our discontinued operations
Income (loss) from discontinued operations	$ 5,641	$ 30,729	$ (5,576)	$ 97,561
Net (income) loss attributable to noncontrolling interests	0	21	(366)	7,593
Net income (loss) from discontinued operations atrributable to Henry Schein, Inc.	5,641	30,708	(5,210)	89,968
Assets transferred
Total current assets of discontinued operations	0		0			$ 1,083,014
Operating lease right-of-use assets	240,126		240,126			0
Investments and other	385,744		385,744			420,367
Total long-term assets of discontinued operations	0		0			1,133,659
Liabilities transferred
Current maturities of long-term debt	109,188		109,188			8,280
Operating lease liabilities	67,374		67,374			0
Accrued expenses:
Total current liabilities of discontinued operations	0		0			577,607
Long-term debt	872,229		872,229			980,344
Operating lease liabilities	182,505		182,505			0
Total long-term liabilities of discontinued operations	0		0			62,453
Redeemable noncontrolling interests	283,325		283,325			219,724	$ 465,585
Henry Schein Animal Health Business [Member]
Summarized financial information for our discontinued operations
Net sales	0	924,114	319,522	2,881,747
Gross profit	0	166,201	59,425	525,408
Operating income (loss)	(1,063)	42,657	(8,588)	130,800
Income tax expense (benefit)	(6,704)	12,767	(2,023)	37,430
Income (loss) from discontinued operations	5,641	30,729	(5,576)	97,561
Net (income) loss attributable to noncontrolling interests	0	(21)	366	(7,593)
Net income (loss) from discontinued operations atrributable to Henry Schein, Inc.	5,641	$ 30,708	(5,210)	$ 89,968
Assets transferred
Cash and cash equivalents					$ 6,815	23,324
Accounts receivable, net					432,812	434,935
Inventories, net					536,637	555,230
Prepaid expenses and other					120,546	69,525
Total current assets of discontinued operations					1,096,810	1,083,014
Property and equipment, net					69,790	68,177
Operating lease right-of-use assets					57,012	0
Goodwill					742,931	739,266
Other intangibles, net					205,793	208,213
Investments and other					120,518	118,003
Total long-term assets of discontinued operations					1,196,044	1,133,659
Total assets of discontinued operations					2,292,854	2,216,673
Liabilities transferred
Accounts Payable					316,162	441,453
Current maturities of long-term debt					657	675
Operating lease liabilities					18,951	0
Accrued expenses:
Payroll and related					36,847	36,888
Taxes					24,060	17,552
Other					80,400	81,039
Total current liabilities of discontinued operations					477,077	577,607
Long-term debt					1,176,105	23,529
Deferred income taxes					17,019	4,352
Operating lease liabilities					38,668	0
Other liabilities					29,209	34,572
Total long-term liabilities of discontinued operations					1,261,001	62,453
Total liabilities of discontinued operations					1,738,078	640,060
Redeemable noncontrolling interests	$ 0		$ 0		$ 28,270	$ 92,432

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Feb. 07, 2019	Sep. 28, 2019	Sep. 28, 2019	Sep. 29, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off			$ 1,120,000	$ 0
Proceeds related to Animal Health Share Sale			$ 361,090	$ 0
Discontinued Operation, Name			Henry Schein Animal Health Business
Henry Schein Animal Health Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off	$ 1,120,000
Proceeds related to Animal Health Share Sale	$ 361,100
Transaction costs related to Animal Health spin-off		$ 300	$ 23,400
Deconsolidation, Nature of Continuing Involvement, Description			In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services.
Henry Schein Animal Health Business [Member] \| Covetrus Inc [Member] \| Henry Schein stockholders and the Share Sale Investors [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		63.00%	63.00%
Henry Schein Animal Health Business [Member] \| Covetrus Inc [Member] \| Vets First Corp [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		37.00%	37.00%

Critical Accounting Policies and Estimates and Accounting Pronouncements Adopted - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2019	Dec. 29, 2018
Operating Leases
Lessee, Operating Lease, Assumptions and Judgments, Discount Rate, Description	As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate.
Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component	When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Lessee, Operating Lease, Assumptions and Judgments, Whether Contract is or Contains Lease	We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration.
Lessee, Operating Lease, Option to Extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
Lessee, Operating Lease, Option to Terminate	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
Lessee, Finance Lease, Description [Abstract]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property, Plant and Equipment, Net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Long-term Debt and Capital Lease Obligations, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term Debt and Capital Lease Obligations
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets	$ 240,126	$ 0
Operating lease liabilities	$ 249,879
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
New Accounting Pronouncement or Change in Accounting Principle, Prior Period Not Restated [true false]	true
Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Fixed List]		Modified Retrospective
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Dec. 30, 2018
Operating lease right-of-use assets		$ 259,900
Operating lease liabilities		267,300
Decrease in prepaid rent		1,100
Decrease in deferred rent liabilities		$ (8,500)
Lease, Practical Expedients, Package [true false]	true
Accounting Standards Update 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Accounting Standards Update 2017-12 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 28, 2019

Sep. 29, 2018

Sep. 28, 2019

Sep. 29, 2018

Debt - Bank credit lines (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 29, 2018
Line of Credit Facility [Line Items]
Bank Credit lines	$ 107,841	$ 951,458
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	75,000	175,000
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	32,841	376,458
Committed Loan Associated with Animal Health Spin-off [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 0	$ 400,000

Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 29, 2018
Debt Instrument [Line Items]
Total long-term debt	$ 981,417	$ 988,624
Less current maturities	(109,188)	(8,280)
Long-term debt	872,229	980,344
Finance lease obligations payable through 2029 with interest rates ranging from 1.45% to 6% at March 30, 2019 and ranging from 1.45% to 6.0% at December 29, 2018	$ 4,205	$ 3,944
Minimum [Member]
Debt Instrument [Line Items]
Finance lease obligations, interest rates	1.64%	1.45%
Maximum [Member]
Debt Instrument [Line Items]
Finance lease obligations, interest rates	19.13%	6.00%
Private placement facilities [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 621,217	$ 628,189
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Total long-term debt	350,000	350,000
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 2.61% to 4.17% at March 30, 2019 and ranging from 2.61% to 4.17% at December 29, 2018 [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 5,995	$ 6,491
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 2.61% to 4.17% at March 30, 2019 and ranging from 2.61% to 4.17% at December 29, 2018 [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.56%	2.61%
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 2.61% to 4.17% at March 30, 2019 and ranging from 2.61% to 4.17% at December 29, 2018 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.50%	4.17%

Debt - Private Placement Facilities - Narrative (Details) - Private placement facilities [Member] $ in Billions	9 Months Ended
	Sep. 28, 2019 USD ($)
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity	$ 1
Debt instrument, maturity date	Sep. 15, 2020
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years
Average term of issuances under private placement facilities	12 years

Leases - Narrative (Details) $ in Millions	9 Months Ended
Leases - Narrative (Details) $ in Millions	Sep. 28, 2019 USD ($)
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Description	We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment.
Lessee, Operating Lease, Option to Extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
Lessee, Operating Lease, Lease Not yet Commenced, Description	buildings and vehicles
Operating lease assets, Lease not yet commenced	$ 6.8
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease, remaining lease term	1 year
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	2 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee operating lease, remaining lease term	16 years
Lessee, Operating Lease, Option to Extend	may include options to extend the leases for up to 10 years
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	10 years

Leases - Maturities of lease liabilities (Details) $ in Thousands	Sep. 28, 2019 USD ($)
Operating Leases
2019 (excluding the nine months ended September 28, 2019)	$ 21,149
2020	69,052
2021	54,082
2022	37,886
2023	26,051
Thereafter	67,075
Total future lease payments	275,295
Finance Leases
2019 (excluding the nine months ended September 28, 2019)	453
2020	1,135
2021	846
2022	434
2023	295
Thereafter	1,372
Total future lease payments	$ 4,535

Leases - Present value of lease liabilities (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 29, 2018
Present value of lease liabilities - Operating Leases
Total future lease payments	$ 275,295
Less imputed interest	(25,416)
Total operating lease liabilities	249,879
Present value of lease liabilities - Finance Leases
Total future lease payments	4,535
Less imputed interest	(330)
Total finance lease liabilities	$ 4,205	$ 3,944

Leases - Future minimum lease payments under non-cancelable operating leases and capital leases (Details) $ in Thousands	Dec. 29, 2018 USD ($)
Operating Leases, Future Minimum Payments Due [Abstract]
2019	$ 62,535
2020	47,686
2021	34,633
2022	25,626
2023	19,560
Thereafter	62,918
Total minimum lease payments	252,958
Finance Leases, Future Minimum Payments Due [Abstract]
2019	976
2020	801
2021	501
2022	305
2023	283
Thereafter	1,430
Total minimum lease payments	4,296
Capital Leases, Future Minimum Payments, Interest Included in Payments	(352)
Total present value of minimum lease payments	$ 3,944

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 28, 2019	Dec. 29, 2018	Dec. 30, 2017
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 283,325	$ 219,724	$ 465,585
Estimate of Fair Value Measurement [Member]
Debt Instrument, Fair Value Disclosure [Abstract]
Fair value of debt	1,089,300	1,940,100
Fair value, measurements, recurring [Member]
Assets [Abstract]
Derivative contracts - assets	5,620	12,533
Total assets	5,620	12,533
Liabilities [Abstract]
Derivative contracts - liabilities	3,629	1,708
Total liabilities	3,629	1,708
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	283,325	219,724
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Derivative contracts - assets	5,620	12,533
Total assets	5,620	12,533
Liabilities [Abstract]
Derivative contracts - liabilities	3,629	1,708
Total liabilities	3,629	1,708
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Total assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 283,325	$ 219,724

Business Acquisitions- Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 28, 2019	Dec. 29, 2018
Business Acquisition [Line Items]
Business acquisition allocated initial goodwill amount	$ 2,441,175	$ 2,081,029
North American Rescue [Member]
Business Acquisition [Line Items]
Business Acquisition, Name of Acquired Entity	North American Rescue
Business acquisition, approximate annual sales of acquired entity	$ 184,000
Business acquisition allocated initial goodwill amount	$ 168,900
Lighthouse 360 [Member] \| Henry Schein One, LLC. [Member]
Business Acquisition [Line Items]
Business Acquisition, Name of Acquired Entity	Lighthouse 360
Business acquisition, approximate annual sales of acquired entity	$ 50,000
Business acquisition allocated initial goodwill amount	$ 143,400

Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
Earnings Per Share (Details) - shares shares in Thousands	Sep. 28, 2019	Sep. 29, 2018	Sep. 28, 2019	Sep. 29, 2018
Weighted-average common shares outstanding:
Basic (in shares)	147,136	152,533	148,603	152,970
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units (in shares)	1,439	1,081	1,317	1,012
Diluted (in shares)	148,575	153,614	149,920	153,982

Income Taxes - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2019	Sep. 29, 2018
Income Tax Disclosure [Abstract]
Effective tax rate (in hundredths)	23.90%	21.80%
Effect of Tax Cuts and Jobs Act [Abstract]
Unrecognized tax benefits	$ 107.6
Unrecognized tax benefits that would affect the effective tax rate if recognized	86.5
Provision for (benefit from) transitional tax		$ 10.0
Total interest	18.3
Total penalties	$ 0.0
Other Information Pertaining to Income Taxes	The tax years subject to examination by major tax jurisdictions include the years 2012 and forward by the U.S. Internal Revenue Service (“IRS”), as well as the years 2008 and forward for certain states and certain foreign jurisdictions. During the quarter ended December 31, 2016 we filed a Mutual Agreement Procedure request with the IRS for assistance from the U.S. Competent Authority for an open Transfer Pricing issue which resulted in a partial settlement during the quarter ended December 30, 2017. We received a 30 Day Letter from the IRS during the quarter ended April 1, 2017 for the remaining open audit issues for the years 2012 and 2013. We filed a Protest with the Appellate Division regarding these issues during the second quarter of 2017. We had an initial Appeals Conference during the third quarter of 2018, of which we are awaiting a final settlement. During the quarter ended December 29, 2018, we submitted the first draft of our proposed Advanced Pricing Agreement covering tax years 2014-2024 to the IRS in which Henry Schein, Inc. and the IRS would agree on an appropriate transfer pricing methodology. We have provided all necessary documentation to the Appellate Division and the Advance Pricing and Mutual Agreement Program to date and are waiting for responses.

Derivatives and Hedging Activities (Details)	9 Months Ended
Derivatives and Hedging Activities (Details)	Sep. 28, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Maximum duration of foreign currency forward contracts	18 months

Stock-Based Compensation - Stock Option Activity (Details) - Employee and director stock options [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 28, 2019 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares) \| shares	3,000
Granted (in shares) \| shares	0
Exercised (in shares) \| shares	(3,000)
Forfeited (in shares) \| shares	0
Outstanding at end of period (in shares) \| shares	0
Ending balance, options exercisable (in shares) \| shares	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 13.63
Granted (in dollars per share) \| $ / shares	0
Exercised (in dollars per share) \| $ / shares	13.63
Forfeited (in dollars per share) \| $ / shares	0
Outstanding at end of period (in dollars per share) \| $ / shares	0
Ending balance, options exercisable (in dollars per share) \| $ / shares	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining contractual life, options outstanding (in years)
Weighted average remaining contractual life, options exercisable (in years)
Stock option outstanding aggregate intrinsic value as of period end \| $	$ 0
Stock option exercisable aggregate intrinsic value as of period end \| $	$ 0

Stock-Based Compensation - Resticted Stock Activity (Details) shares in Thousands	9 Months Ended
	Sep. 28, 2019 $ / shares shares
Time Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,513
Granted (in shares) \| shares	449
Vested (in shares) \| shares	(338)
Forfeited (in shares) \| shares	(204)
Ending balance outstanding (in shares) \| shares	1,420
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 57.94
Granted (in dollars per share)	59.47
Vested (in dollars per share)	55.57
Forfeited (in dollars per share)	60.39
Ending balance outstanding (in dollars per share)	58.66
Intrinsic value (in dollars per share)	$ 62.58
Performance Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,163
Granted (in shares) \| shares	656
Vested (in shares) \| shares	(185)
Forfeited (in shares) \| shares	(155)
Ending balance outstanding (in shares) \| shares	1,479
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 40.26
Granted (in dollars per share)	60.04
Vested (in dollars per share)	66.52
Forfeited (in dollars per share)	61.37
Ending balance outstanding (in dollars per share)	61.41
Intrinsic value (in dollars per share)	$ 62.58

Legal Proceedings - Narrative (Details)	3 Months Ended		9 Months Ended		12 Months Ended
Legal Proceedings - Narrative (Details)	Sep. 28, 2019 USD ($) claims	Sep. 29, 2018 USD ($)	Sep. 28, 2019 USD ($) claims	Sep. 29, 2018 USD ($)	Dec. 29, 2018 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Litigation settlements	$ 0	$ 38,488,000	$ 0	$ 38,488,000
Revenues	$ 2,508,767,000	$ 2,355,565,000	$ 7,316,862,000	$ 6,945,047,000
Loss Contingency, Management's Assessment and Process			As of September 28, 2019, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.
Class Action Complaints Against Patterson Companies, Inc., Benco Dental Supply Co. and Henry Schein, Inc. [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			January 2016
Loss Contingency, Name of Defendant			Patterson Companies, Inc. (“Patterson”), Benco Dental Supply Co. (“Benco”) and Henry Schein, Inc
Loss Contingency, Name of Plaintiff			class action complaints
Loss Contingency, Allegations			each of these complaints alleges, among other things, that defendants conspired to fix prices, allocate customers and foreclose competitors by boycotting manufacturers, state dental associations and others that deal with defendants’ competitors
Archer and White Sales, Inc. v. collectively, the Danaher Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			August 31, 2012
Loss Contingency, Name of Defendant			Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”)
Loss Contingency, Name of Plaintiff			Archer and White Sales, Inc.
Loss Contingency, Allegations			Archer alleges aconspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights.
Archer filed amended complaint adding Patterson and Benco as Defendants [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			August 1, 2017
Loss Contingency, Name of Defendant			adding Patterson and Benco as defendants
Loss Contingency, Name of Plaintiff			Archer
Loss Contingency, Allegations			alleging that Henry Schein, Patterson, Benco and Burkhart conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer.
Archer filed second amended complaint under seal [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			October 30, 2017
Loss Contingency, Name of Defendant			The named parties and causes of action are the same as the August 1, 2017 amended complaint.
Loss Contingency, Name of Plaintiff			Archer
Loss Contingency, Allegations			add additional allegations that it believes support its claims
IQ Dental Supply, Inc V. Henry Schein, Inc. Patterson Companies, Inc. [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			August 17, 2017
Loss Contingency, Name of Defendant			Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company
Loss Contingency, Name of Plaintiff			IQ Dental Supply, Inc.
Loss Contingency, Allegations			Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental (“SourceOne”).
United States Federal Trade Commission [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			February 12, 2018
Loss Contingency, Name of Defendant			Benco Dental Supply Co., Henry Schein, Inc. and Patterson Companies, Inc.
Loss Contingency, Name of Plaintiff			United States Federal Trade Commission
Loss Contingency, Allegations			The FTC alleges, among other things, that defendants violated U.S. antitrust laws by conspiring, and entering into an agreement, to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners.
Salkowitz v. Henry Schein, Inc. et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			March 7, 2018
Loss Contingency, Name of Defendant			Joseph Salkowitz, individually and on behalf of all others similarly situated
Loss Contingency, Name of Plaintiff			Henry Schein, Inc., Stanley M. Bergman and Steven Paladino
Loss Contingency, Allegations			The complaint alleged, among other things, that the defendants had made materially false and misleading statements about Henry Schein’s business, operations and prospects during the Class Period, including matters relating to the issues in the antitrust class action and the FTC action described above, thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities.
Marion Diagnostic Center, LLC v. Dickinson, and Co., 3:18-cv-01509 (S.D. Ill) [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			May 3, 2018
Loss Contingency, Name of Defendant			Marion Diagnostic Center, LLC, et al.
Loss Contingency, Name of Plaintiff			Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton DistributorCo-Conspirators.
Loss Contingency, Allegations			The complaint alleges that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels.
The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			May 29, 2018
Loss Contingency, Name of Defendant			Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants.
Loss Contingency, Name of Plaintiff			The County of Summit, Ohio et al.
Loss Contingency, Allegations			Summit County alleges that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs.
Loss Contingency, Settlement Agreement, Terms			On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, will establish and donate $1 million to a Pain Management Education Foundation dedicated to making grants to programs within Summit County focused on (I) supporting and aggregating research around best practices for pain management, including the prescription of opioids and alternatives: (II) educating dentists and physicians, clinical associates, patients and patient networks on those best practices along with the risks of opioid addiction and alternative pain management treatment options for key indications; and ‎(III) offering grants to develop and offer training to dentists and physicians or other qualified professionals to qualify a practitioner for a waiver to prescribe or dispense buprenorphine medications. Henry Schein will pay $250,000 of Summit County’s expenses.
Donation amount to Pain Management Education Foundation			$ 1,000,000
Litigation Settlement, Amount Awarded to Other Party			$ 250,000
Actions consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Name of Defendant			Henry Schein and/or one or more of its affiliated companies
Loss Contingency, Allegations			allege claims similar to those alleged in the County of Summit Action
Actions consolidated in the MultiDistrict Litigation [Member] \| Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims	100		100
Maximum sales of opioids in North America during the year, percentage					10.00%
Actions consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues					$ 9,400,000,000
Kramer v. Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and Unnamed Co-Conspirators [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			October 9, 2018
Loss Contingency, Name of Defendant			Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and Unnamed Co-Conspirators
Loss Contingency, Name of Plaintiff			Kramer
Loss Contingency, Allegations			The complaint alleges that members of the proposed class, comprised of purchasers of dental services from dental practices in California, suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged California dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the California class purchasing dental services.
R. Lawrence Hatchett, M.D. against Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			January 29, 2019
Loss Contingency, Name of Defendant			Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators
Loss Contingency, Name of Plaintiff			R. Lawrence Hatchett, M.D.
Loss Contingency, Allegations			The complaint alleges that members of the proposed class suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged Illinois dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the class.
City of Hollywood Police Officers Retirement System V. Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Lawsuit Filing Date			September 30, 2019
Loss Contingency, Name of Defendant			Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola
Loss Contingency, Name of Plaintiff			City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated
Loss Contingency, Allegations			The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger.

Subsequent Events - Narrative (Details) - Subsequent Event [Member]	Oct. 01, 2019 USD ($)
Subsequent Event [Line Items]
Subsequent Event, Date	Oct. 01, 2019
Subsequent Event, Description	the Company sold an equity investment in Hu-Friedy Mfg. Co., LLC, a manufacturer of dental instruments and infection prevention solutions. Our investment was non-controlling, we were not involved in running the business and had no representation on the board of directors. We estimate that in the fourth quarter of 2019 we will record a pretax gain from this sale in the range of $225 million to $275 million. Our final calculation of the gain will take into account the accounting treatment of contingent consideration associated with the transaction and the appropriate income tax treatment.
Minimum [Member] \| Forecast [Member] \| Hu-Friedy Mfg. Co., LLC [Member]
Subsequent Event [Line Items]
Equity Method Investment, Pretax gain on sale	$ 225,000,000
Maximum [Member] \| Forecast [Member] \| Hu-Friedy Mfg. Co., LLC [Member]
Subsequent Event [Line Items]
Equity Method Investment, Pretax gain on sale	$ 275,000,000